

## REMARKS

Prior to entry of the present amendment, claim 1-23 are pending. Claims 11-23, due to a restriction requirement, are withdrawn from consideration. Claims 9 and 10 are objected to and claims 1-10 are rejected under 37 C.F.R. § 103. Applicants address each of the bases for rejection as follows.

### Claim Amendments

Claim 1 has been amended to recite the word “and” between steps (e) and (f), to incorporate the features of claim 2, and to correct a minor typographical error. In view of the amendment to claim 1, claim 2 has been canceled. Claims 9 and 10 have also been canceled. No new matter has been added by the present amendments.

Applicants reserve the right to pursue any canceled subject matter in this or in a continuing application.

### Information Disclosure Statement

The Office objects to the GenBank references listed on the form PTO-1449 enclosed with the information disclosure statement filed on October 4, 2004 for not including a publication date. The form PTO-1449 submitted with the concurrently filed information disclosure statement includes dated GenBank entries. Applicants respectfully request consideration of the cited references.

### Objection to the Specification

The Office states (pages 2 and 3):

The specification contains sequence disclosures (e.g., page 101-103) that are encompassed by the definitions for nucleotide and/or amino acid sequences ... but are not present in the Sequence Listing and/or identified in the specification by sequence identifier numbers.

In response, Applicants direct the Office's attention to Applicants' September 23, 2004 reply to the Notice to File Missing Parts mailed on June 22, 2004. (For the Office's convenience, a copy of the September 23<sup>rd</sup> reply is enclosed.) In particular, Applicants note that, in the preliminary amendment filed with the September 23<sup>rd</sup> reply, the specification was amended to identify each nucleic acid or amino acid sequence (including those on pages 101-103 of the specification) by a unique sequence identifier. Applicants also filed a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821-1.825 and the required sequence statement. Applicants submit that the specification, as amended in the September 23<sup>rd</sup> reply meets the sequence requirements of 37 C.F.R. §§ 1.821-1.825. This basis for objection may be withdrawn.

### Objection to the Claims

Claims 9 and 10 are objected to based on the assertion that they fail to further limit the claim from which they depend. Claims 9 and 10 have been canceled. This basis for rejection, therefore, is moot.

Rejection under 35 U.S.C. § 103

Claims 1-10 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Ahlert et al. (Cancer Res. 50:5962-5968, 1990; “Ahlert”) as evidenced by Kroumpouzou et al. (Pigment Cell Res. 7:348-353, 1994; “Kroumpouzou”). Applicants respectfully submit that claim 1, as amended, and its dependent claims are free of this basis for rejection.

Claim 1, as amended, reads as follows.

1. A method of producing a tumor host range (T-HR) mutant virus, wherein said T-HR mutant virus is unable to propagate in normal cells, but is able to propagate in abnormally proliferating cells, said method comprising the steps of:

- (a) providing a wild-type viral DNA;
- (b) introducing random mutations in said wild-type viral DNA, thereby obtaining a collection of uncharacterized mutant viruses;
- (c) infecting *uncharacterized* abnormally proliferating cells with said collection of mutant viruses to amplify said mutant viruses;
- (d) selecting mutant viruses that have the ability to proliferate in said *uncharacterized* abnormally proliferating cells from said collection by plaque isolation;
- (e) infecting normally proliferating cells with mutant viruses selected in step (d); and
- (f) identifying mutant viruses from step (e) that do not proliferate in said normally proliferating cells, wherein said identified mutant viruses are identified as a T-HR mutant viruses. (Emphasis added.)

The specification, at page 17, lines 5-8, states:

“Uncharacterized abnormally proliferating cell,” as used herein, refers to a cell where *the cause of the abnormal proliferation is unknown*. For example, *the genetic alteration that results in abnormal proliferation has not been identified*. However, other features of the cell may be characterized. (Emphasis added.)

Applicants submit that neither Ahlert nor Kroumpouzou, alone or in combination, renders the presently claimed invention obvious.

Ahlert describes infecting abnormally proliferating MeWo cells with a collection of mutant viruses. The Office relies on Kroumpouzou for teaching that “MeWo cells do express an oncogene *c-myc*, and lost the biologically active tumor suppressor protein p53.” While the Office apparently asserts that the cause of abnormal proliferation of MeWo cells is unknown, Applicants submit that the description in Kroumpouzou clearly indicates that genetic alterations that result in abnormal proliferation of MeWo cells have been identified. In particular, Table 1 of Kroumpouzou describes MeWo cells as lacking expression of the p53 tumor suppressor while expressing the *c-myc* oncogene. In view of Kroumpouzou, Applicants submit that Ahlert fails to teach or suggest using *uncharacterized* abnormally proliferating cells in a method of producing a virus that is unable to propagate in the uncharacterized abnormally proliferating cells.

To establish a *prima facie* case of obviousness under § 103, the Office must demonstrate that the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious, at the time the invention was made, to a person having ordinary skill in the art. 35 U.S.C. § 103(a) (Supp. III 1997); *In re Dembiczak*, 175 F.3d 994, 998, 50 U.S.P.Q.2d 1614, 1616 (Fed. Cir. 1999), *abrogated on other grounds by In re Gartside*, 203 F.3d 1305, 53 U.S.P.Q.2d 1769 (Fed. Cir. 2000). In the present case, the references, even if combined, fail to teach or suggest all of the

elements of the presently claimed invention. In particular, the references fail to teach or suggest infecting *uncharacterized* abnormally proliferating cells with a collection of mutant viruses. Applicants submit that the cited references fail to establish a *prima facie* case of obviousness for claim 1 and its dependent claims. The 35 U.S.C. § 103 rejection of claims 1 and 3-8 should be withdrawn.

CONCLUSION


Applicants submit that the application is now in condition for allowance, and such action is hereby respectfully requested.

Enclosed is a Petition to extend the period for replying to the Office Action for three (3) months, to and including April 5, 2007, and a check in payment of the required extension fee.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: April 4, 2007

  
\_\_\_\_\_  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

COPY



PATENT  
ATTORNEY DOCKET NO. 00742/062004

Certificate of Mailing: Date of Deposit: September 21, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis  
Printed name of person mailing correspondence

Janet D'Annunzio-Ellis  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thomas L. Benjamin      Art Unit: 1632  
Serial No.: 10/828,815      Examiner: Not Assigned  
Filed: April 21, 2004      Customer No.: 21559  
Title: DIAGNOSING AND TREATING CANCER CELLS USING  
MUTANT VIRUSES

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME


Pursuant to 37 C.F.R. § 1.136, Applicant hereby petitions that the period for replying to the Notice to File Missing Parts of Application that was mailed in connection with the above-captioned application on June 22, 2004 be extended for one (1) month, to and including September 22, 2004.

COPY

Enclosed is a check for \$55.00 for the fee required by 37 C.F.R. § 1.17(a). If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: September 20, 2004

  
\_\_\_\_\_  
Kristina Bieker-Brady, Ph.D., P.C.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045





COPY

PATENT  
ATTORNEY DOCKET NO. 00742/062004

Certificate of Mailing: Date of Deposit: September 21, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis  
Printed name of person mailing correspondence

Janet D'Annunzio-Ellis  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Thomas L. Benjamin	Art Unit:	1632
Serial No.:	10/828,815	Examiner:	Not Assigned
Filed:	April 21, 2004	Customer No.:	21559
Title:	DIAGNOSING AND TREATING CANCER CELLS USING MUTANT VIRUSES		

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REPLY TO NOTICE TO FILE MISSING PARTS OF APPLICATION

In reply to the Notice to File Missing Parts of Application that was mailed in connection with the above-captioned application on June 22, 2004, a copy of which is enclosed, Applicant, as a small entity, submits herewith the following:

- A Combined Declaration and Power of Attorney in compliance with 37 C.F.R. § 1.63.
- Payment of the surcharge of \$65.00 for late filing of the declaration.
- A Sequence Listing and diskette.
- A Sequence Statement.

COPY

- A Preliminary Amendment.
- One Replacement Drawing.
- Petition for Extension of Time of one (1) Month with check for the \$55.00 extension fee.


If there are any additional charges or any credits, please apply them to Deposit

Account No. 03-2095.

Respectfully submitted,

Date:

September 10, 2004



Kristina Bieker-Brady, Ph.D., P.C.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



COPY

SPW

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/828,815	04/21/2004	Thomas L. Benjamin	00742/062004

21559  
CLARK & ELBING LLP  
101 FEDERAL STREET  
BOSTON, MA 02110

CONFIRMATION NO. 7702

## FORMALITIES LETTER



\*OC000000013008081\*

Date Mailed: 06/22/2004

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

09/24/2004 MHEKONEN 00000138 10828815

FILED UNDER 37 CFR 1.53(b)

01 FC:2051

65.00 OP

*Filing Date Granted***Items Required To Avoid Abandonment:**

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600

- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

**SUMMARY OF FEES DUE:**

Total additional fee(s) required for this application is **\$65** for a Small Entity

- **\$65** Late oath or declaration Surcharge.

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

---

*A copy of this notice **MUST** be returned with the reply.*

B.H.  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202  
PART 2 - COPY TO BE RETURNED WITH RESPONSE

# COPY



PATENT  
ATTORNEY DOCKET NO. 00742/062004

## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled **DIAGNOSING AND TREATING CANCER CELLS USING MUTANT VIRUSES**, the specification of which was filed on April 21, 2004 as Application Serial No. 10/828,815.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with 37 C.F.R. § 1.56.

**FOREIGN PRIORITY RIGHTS:** I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f), or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below, and have also identified below any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Country	Serial Number	Filing Date	Priority Claimed?
			Yes/No

**PROVISIONAL PRIORITY RIGHTS:** I hereby claim priority benefits under 35 U.S.C. § 119(e) of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

Serial Number	Filing Date	Status
60/339,140	December 10, 2001	Abandoned
60/216,723	July 7, 2000	Abandoned

**NON-PROVISIONAL PRIORITY RIGHTS:** I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Filing Date	Status
10/765,520	January 27, 2004	Pending

COPY


Serial Number	Filing Date	Status
10/316,532	December 10, 2002	Pending
09/988,117	November 16, 2001	Abandoned
09/812,471	March 19, 2001	Abandoned
09/812,633	March 19, 2001	Abandoned

I hereby appoint the attorneys and/or agents associated with customer number **21559** to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all correspondence relating to this application to the address associated with customer number **21559**, which is Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110.

Address all telephone calls to: Kristina Bieker-Brady, Ph.D. at 617-428-0200.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Thomas L. Benjamin	Cambridge, MA U.S.A.	595 Putnam Avenue Cambridge, MA 02139	United States
Signature: 			Date: 6/24/04

COPY



PATENT  
ATTORNEY DOCKET NO. 00742/062004

Certificate of Mailing: Date of Deposit: September 21, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis  
Printed name of person mailing correspondence

*Janet D'Annunzio-Ellis*  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Thomas L. Benjamin	Art Unit:	1632
Serial No.:	10/828,815	Examiner:	Not Assigned
Filed:	April 21, 2004	Customer No.:	21559
Title:	DIAGNOSING AND TREATING CANCER CELLS USING MUTANT VIRUSES		

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Prior to examination of the above-captioned application, kindly amend the application as follows.

AMENDMENTS TO THE SPECIFICATION:

Insert the sequence listing submitted with the concurrently filed Statement under 37 C.F.R. §§ 1.821-1.825 at the end of the specification.

Amend the paragraph beginning on page 10, line 6, as follows.

In another aspect, the invention features an isolated nucleic acid encoding a Death Inducer with SAP Domain amino acid sequence, where this Death Inducer with SAP Domain amino acid sequence is at least 30% identical to the amino acid sequence of ~~SEQ ID NO:2~~ SEQ ID NO:33 or ~~SEQ ID NO:4~~ SEQ ID NO:35 and induces DNA condensation and apoptosis in a mammalian cell. However, this Death Inducer with SAP Domain amino acid sequence may also include the amino acid sequence of ~~SEQ ID NO:2~~ SEQ ID NO:33 or ~~SEQ ID NO:4~~ SEQ ID NO:35. In addition, the nucleic acid encoding the Death Inducer with SAP Domain amino acid may include the nucleic acid sequence of ~~SEQ ID NO:1~~ SEQ ID NO:32 or ~~SEQ ID NO:3~~ SEQ ID NO:34.

Amend the paragraph beginning on page 10, line 15, as follows.

In yet another aspect, the invention features a method of killing an abnormally proliferating cell. This method involves contacting the abnormally proliferating cell with a *Death Inducer with SAP Domain* nucleic acid sequence, where this contacting results in the expression of a DIS polypeptide in the abnormally proliferating cell. The *Death Inducer with SAP Domain* nucleic acid sequence may include, for example, the nucleic acid sequence of ~~SEQ ID NO:1~~ SEQ ID NO:32 or ~~SEQ ID NO:3~~ SEQ ID NO:34. In



addition, the abnormally proliferating cell may be an endometrial, prostate, or ovarian cell.

Amend the paragraph beginning on page 11, line 12, as follows.

In yet another aspect, the invention features a method of decreasing virus, for example, tumor virus, replication and dissemination. This method includes the step of contacting a cell infected with a virus with a T-HR mutant target gene nucleic acid sequence, where this contacting results in the expression of a T-HR mutant target gene encoded polypeptide in the cell infected with the virus and prevents the virus from replicating and disseminating, or, for instance, from replicating or disseminating. For example, the virus may be a DNA tumor virus. In addition, in desirable embodiments, the T-HR mutant target gene nucleic acid sequence may be a *Taz*, a *GAP SH3 binding protein*, a *nucleolin*, a *Vesicle Associated Protein 1*, or a *Death Inducer with SAP Domain* nucleic acid sequence, such as the *Death Inducer with SAP Domain* nucleic acid sequence of ~~SEQ ID NO:1~~ SEQ ID NO:32 or ~~SEQ ID NO:3~~ SEQ ID NO:34.

Amend the paragraph beginning on page 22, line 14, as follows.

By a “*DIS* nucleic acid sequence” or “*Death Inducer with SAP domain* nucleic acid sequence,” as used herein is meant a nucleic acid sequence that is at least 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical to a nucleic acid sequence provided of ~~SEQ ID NO:1~~ SEQ ID NO:32 or ~~SEQ ID NO:3~~ SEQ ID NO:34 over a region comprising at least 200, 300, 500, 750, 1000, 1500, 2000, 2500, 3000, or 3500 contiguous

# COPY

nucleotides. In addition, a “*DIS* nucleic acid sequence” may be identical to the nucleic acid sequence of ~~SEQ ID NO:1~~ SEQ ID NO:32 or ~~SEQ ID NO:3~~ SEQ ID NO:34. In desirable embodiments, a “*DIS* nucleic acid sequence” is a human or a mouse *DIS* nucleic acid sequence that is at least 75%, 80%, 85%, 90%, or 95% identical to the human *DIS* nucleic acid sequence of ~~SEQ ID NO:3~~ SEQ ID NO:34, or to the murine *DIS* nucleic acid sequence of ~~SEQ ID NO:1~~ SEQ ID NO:32, over a region encompassing at least 1000, 2000, 3000, or 3500 contiguous nucleotides, and encodes a protein which induces DNA condensation and apoptosis in mammalian cells.

Amend the paragraph beginning on page 22, line 27, as follows.

By a “*DIS* polypeptide,” a “Death Inducer with SAP domain polypeptide,” a “*DIS* amino acid sequence,” or a “Death Inducer with SAP domain amino acid sequence,” as used herein is meant an amino acid sequence that is at least 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical to the amino acid sequence of ~~SEQ ID NO:2~~ SEQ ID NO:33 or ~~SEQ ID NO:4~~ SEQ ID NO:35 over a region comprising at least 50, 75, 100, 200, 300, 500, 700, 900, or 1200 contiguous amino acids. In addition, a “*DIS* polypeptide” may be identical to the amino acid sequence of ~~SEQ ID NO:2~~ SEQ ID NO:33 or ~~SEQ ID NO:4~~ SEQ ID NO:35. In desirable embodiments, a “Death Inducer with SAP domain (*DIS*) polypeptide” or a “Death Inducer with SAP domain (*DIS*) amino acid sequence” is a human or a mouse *DIS* polypeptide or amino acid sequence that is at least 30%, 50%, 60%, 70%, 80%, 90%, or 95% identical to the human *DIS* amino acid sequence of ~~SEQ ID NO:4~~ SEQ ID NO:35, or the mouse *DIS* amino acid sequence of

# COPY

~~SEQ ID NO: 2~~ SEQ ID NO:33, over a region encompassing 500, 700, 900, or 1200 contiguous amino acids, and induces DNA condensation and apoptosis in mammalian cells.

Amend the paragraph beginning on page 30, line 14, as follows.

Fig. 2A is sequence comparison between a region of the wild-type and TMD25 polyoma virus large T antigen nucleic acid and amino acid sequences and shows the 20 bp sequence duplication responsible for the TMD25 mutation (SEQ ID NOS:9-12).

Amend the paragraph beginning on page 30, line 21, as follows.

Fig. 2C is a series of large T antigen amino acid sequences and shows the deletion analysis of the TMD25 mutant (SEQ ID NOS:13-21).

Amend the paragraph beginning on page 32, line 22, as follows.

~~Fig. 22~~Figs. 22A-22E is are the sense (~~SEQ ID NO:1~~ SEQ ID NO:32) and the antisense strand of the murine *DIS* nucleic acid sequence as well as the corresponding amino acid sequence (~~SEQ ID NO:2~~ SEQ ID NOS:33 and 36-45).

Amend the paragraph beginning on page 32, line 25, as follows.

~~Fig. 23~~Figs. 23A and 23B is are the murine *DIS* nucleic acid sequence (~~SEQ ID NO:1~~ SEQ ID NO:32).

# COPY

Amend the paragraph beginning on page 32, line 26, as follows.

~~Fig. 24~~Figs. 24A-24E ~~is~~ are the murine *DIS* nucleic acid sequence (~~SEQ ID NO: 1~~  
SEQ ID NO:32) and the amino acid sequence encoded by the open reading frame of  
murine DIS (~~SEQ ID NO: 2~~ SEQ ID NO:33).

Amend the paragraph beginning on page 33, line 1, as follows.

~~Fig. 25~~Figs. 25A-25E ~~is~~ are the sense (~~SEQ ID NO: 3~~ SEQ ID NO:34) and the  
antisense strand human *DIS* nucleic acid sequence as well as the corresponding amino  
acid sequence (~~SEQ ID NO:4~~ SEQ ID NOS:35 and 46-53).

Amend the paragraph beginning on page 33, line 4, as follows.

~~Fig. 26~~Figs. 26A and 26B ~~is~~ are the human *DIS* nucleic acid sequence (~~SEQ ID~~  
~~NO: 3~~ SEQ ID NO:34).

Amend the paragraph beginning on page 33, line 5, as follows.

~~Fig. 27~~Figs. 27A-27D ~~is~~ are the human *DIS* nucleic acid sequence (~~SEQ ID NO: 3~~  
SEQ ID NO:34) and the amino acid sequence encoded by the open reading frame of  
human DIS (~~SEQ ID NO: 4~~ SEQ ID NO:35).

Amend the paragraph beginning on page 33, line 16, as follows.

~~Fig. 32~~Figs. 32A and 32B ~~is~~ are a series of Western blots showing that DIS,  
PARP, and LaminB are cleaved in BMK and HeLa cells upon induction of apoptosis by

COPY

staurosporine (A), and that caspase-3 and caspase-8 inhibitors can inhibit DIS cleavage (B).

Amend the paragraph beginning on page 47, line 27, as follows.

Furthermore, when we induced apoptosis in BMK and HeLa cells with staurosporine, we observed that DIS was degraded and that PARP and LaminB were cleaved (Fig. 32, panel A). Both PARP and LaminB are cleaved by caspases during apoptosis. We also observed that caspase-3 and caspase-8 inhibitors inhibited cleavage of DIS (Fig. 32, panel B). In view of these results, we analyzed the structure of human and mouse DIS and identified a number of caspase-3 and caspase-8 cleavage sites (Fig. 33). *In vitro* caspase cleavage experiments showed that DIS is sensitive to caspase-3 and that the first caspase-3 site (at amino acid 691 in human DIS (~~SEQ ID NO: 4~~ SEQ ID NO:35) and amino acid 689 in murine DIS (~~SEQ ID NO: 2~~ SEQ ID NO:33)) is used for cleavage (Fig. 34). Consequently, DIS is likely to function in regulating apoptosis and may be used in methods to diagnose and treat proliferative disorders.

Amend the paragraph beginning on page 71, line 23, as follows.

We generated TAZ knock out mice by replacing exon 2 (which encodes amino acids 1-144 of murine DIS; ~~SEQ ID NO: 2~~ SEQ ID NO:33) of the mouse TAZ gene with the pSAbeta-galpGKneopGKdta positive-negative selection vector (Figure 35). The TAZ knock out construct was transfected into an Embryonic Stem (ES) cell line and two positive ES clones were obtained and confirmed by PCR and by Southern blot. A

# COPY

Southern blot for the *neo* gene also confirmed that only exon 2 of TAZ was replaced. We performed microinjections with these ES clones and obtained chimeric mice. Nine F1 TAZ<sup>+/-</sup> mice were obtained from different chimeric mice and these mice were mated to each other to generate TAZ<sup>-/-</sup> knockout mice.

Amend the paragraph beginning on page 101, line 25, as follows.

Total RNAs from SK-Vector and SK-P150 clones were amplified using primer pairs (5'-CGT CAC CTG AGG TGA CAC AGC AAA GC-3' (SEQ ID NO:22) and 5'-CGC TTC CAG GAC TGC AGG CTT CCT G-3' (SEQ ID NO:23). G3PDH was amplified using (5'-CAG ACC CCA AAT CTG CAG ATA CTC AG-3' (SEQ ID NO:24) and 5'-CAC TGG AAT TGG AAC TCT TCT GTC GAG-3' (SEQ ID NO:25)). Amplification mixtures from cycle numbers with linear amplification were used for comparing relative quantities of transcripts. Amplified G3PDH cDNA was used as an internal control to normalize the amount of p21 cDNA. The ratio of p21 versus G3PDH is the average of three linear amplification cycles.

Amend the paragraph beginning on page 102, line 22, as follows.

ChIP was performed as described previously by Weinmann et al., Methods 26:37-47, 2003). P19 cells extracts were used for ChIP. Chromatin elute was amplified using mouse p21 promoter specific primers: 5'-GAA GTA GGA GTC ACC GTC CTG TTT ACC-3' (SEQ ID NO:26) and 5'-GAT GTC TCT GTA TAG CCC TGG CTG TC-3' (SEQ ID NO:27) for 45 cycles. As a non-specific control, GAPD (glyceraldehyde-3-

phosphate dehydrogenase) gene was amplified with 5'-GCT GAA CGG GAA GCT CAC TGG CAT GG-3' (SEQ ID NO:28) and 5'-GAG GTC CAC CAC CCT GTT GCT GTA GC-3' (SEQ ID NO:29).

Amend the paragraph beginning on page 103, line 2, as follows.

Two p150 specific siRNA duplexes were made (Dharmacon Research, CO) 5'-AAG GAG AUG GAC AGU AAU GAG-3' (SEQ ID NO:30) and 5'-AAC CCC AUU ACC UCC AGA AUC-3' (SEQ ID NO:31) and transfected together into HOSE cells using Oligofectamine (Invitrogen) follow manufacturer's suggestions. The cells were serum-starved (0.2% serum) for 48 hrs and stimulated with 10% FBS and 100 uM BrdU. After 18hrs, cells were fixed and stained for BrdU and DAPI. p21 was detected by immunoprecipitation followed by Western blot. P150 and tubulin were detected directly by Western blot.

COPY

AMENDMENTS TO THE DRAWINGS:

Please amend drawing sheet 28 of 54 to be labeled Fig. 24E.



COPY

REMARKS

Applicant has amended the specification to refer to each nucleic acid or amino acid sequence by a sequence identification number.


Applicant also corrects a typographical error in the labeling of Figure 24E. As required under 37 C.F.R. § 1.121(d), enclosed is a corrected drawing which, in the header, is labeled "Replacement Sheet." On this Replacement Sheet the labeling has been changed from "Fig. 13E" to "Fig. 24E." No new matter has been added by these amendments.

Enclosed, with the concurrently filed reply to Notice to File Missing Parts, are a petition to extend the period for replying to the Notice by one month, to and including September 22, 2004, and a check in the amount of the required fee.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: September 20, 2004



Kristina Bieker-Brady, Ph.D., P.C.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



COPY

## FIG. 24E

3244 ctccagttactagaggagaaaaacagatgaagatgggaaaactata  
L Q L L E E K T D E D G K T I  
3289 ttaaacttggagaactctaacaaaagcctctctgtgaacttaga  
L N L E N S N K S L S G E L R  
3334 gaggtcaaaaaagaccttgggtcaattacaagaaaacctggaggtt  
E V K K D L G Q L Q E N L E V  
3379 tcagaaaacatgaatttgaatttgaacaaattgaataaaaca  
S E N M N L Q F E N Q L N K T  
3424 ctcagaaacttatctacagttatggatgatatccacactgtcctc  
L R N L S T V M D D I H T V L  
3469 aaaaaggataatgtaaagagtgaagacagagatgagaaatccaag  
K K D N V K S E D R D E K S K  
3514 gagaacggctcaggtgtatga 3534.  
E N G S G V

CACAGTGCACTTGGGGATGAGTGTGTTAATAGTGTACTATAAACAAAATAATCAT  
GAGATGGGAATGTTTCACGGCAGTGCATGCTTGACTTTAGTAGTATAAACATATA  
TGTTAGTTCAAATGATGTATAAAGTTTTATGAATGTGAGTCTGCTTTTGAAAATT  
GCCTGTAATTTCTAGCATTCAAATTATTAATACTCACTGAGTGAAGAATTTTGC  
ATTGCAAAACCTTTTAGGATGAACTTGGTTATAGTTTCCCAATAAAGTTCATCA  
GTGTCATTGACAATGACAAGTAATTAAACCAAAAAAAAAAAAAAAAAACAAACACCAA  
CCAGG



COPY

PATENT  
ATTORNEY DOCKET NO. 00742/062004

Certificate of Mailing: Date of Deposit: September 21, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis  
Printed name of person mailing correspondence

Janet D'Annunzio-Ellis  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Thomas L. Benjamin	Art Unit:	1632
Serial No.:	10/828,815	Examiner:	Not Assigned
Filed:	April 21, 2004	Customer No.:	21559
Title:	DIAGNOSING AND TREATING CANCER CELLS USING MUTANT VIRUSES		

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. §§ 1.821-1.825

In reply to the Notice to File Missing Parts of a Nonprovisional Application that was mailed in connection with the above-captioned application on June 22, 2004, enclosed is a Sequence Listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of 28 pages.

As required by 37 C.F.R. § 1.821(c), the Sequence Listing appears as a separate part of the application. Each sequence in the application appears separately in the

COPY

Sequence Listing, and each sequence in the Sequence Listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the Sequence Listing in computer readable form.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form of the Sequence Listing are the same as the contents of the paper copy.


As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

September 10, 2004



Kristina Bieker-Brady, Ph.D., P.C.

Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



COPY

SEQUENCE LISTING

<110> Benjamin, Thomas L.

<120> Diagnosing and Treating Cancer Cells  
Using Mutant Viruses

<130> 00742/062004

<140> 10/828,815

<141> 2004-04-21

<150> 10/765,520

<151> 2004-01-27

<150> 10/316,532

<151> 2002-12-10

<150> 09/812,471

<151> 2001-03-19

<150> 09/988,117

<151> 2001-11-16

<150> 60/339,140

<151> 2001-12-10

<150> 09/812,633

<151> 2001-03-19

<150> 60/216,723

<151> 2000-07-07

<160> 53

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1005

<212> PRT

<213> Homo Sapiens

<400> 1

Met	Ala	His	Glu	Ser	Glu	Arg	Ser	Ser	Arg	Leu	Gly	Val	Pro	Ala	Gly
1				5					10					15	
Glu	Pro	Ala	Glu	Leu	Gly	Gly	Asp	Ala	Ser	Glu	Glu	Asp	His	Pro	Gln
			20				25						30		
Val	Cys	Ala	Lys	Cys	Cys	Ala	Gln	Phe	Thr	Asp	Pro	Thr	Glu	Phe	Leu
			35				40					45			
Ala	His	Gln	Asn	Ala	Cys	Ser	Thr	Asp	Pro	Pro	Val	Met	Val	Ile	Ile
			50			55					60				
Gly	Gly	Gln	Glu	Asn	Pro	Asn	Asn	Ser	Ser	Ala	Ser	Ser	Glu	Pro	Arg
65				70						75				80	
Pro	Glu	Gly	His	Asn	Asn	Pro	Gln	Val	Met	Asp	Thr	Glu	His	Ser	Asn
				85					90					95	
Pro	Pro	Asp	Ser	Gly	Ser	Ser	Val	Pro	Thr	Asp	Pro	Thr	Trp	Gly	Pro
				100				105						110	
Glu	Arg	Arg	Gly	Glu	Glu	Ser	Ser	Gly	His	Phe	Leu	Val	Ala	Ala	Thr

# COPY

	115	120	125
Gly Thr Ala Ala Gly Gly Gly Gly Gly Leu Ile Leu Ala Ser Pro Lys			
130		135	140
Leu Gly Ala Thr Pro Leu Pro Pro Glu Ser Thr Pro Ala Pro Pro Pro			
145	150	155	160
Pro Pro Pro Pro Pro Pro Pro Gly Val Gly Ser Gly His Leu Asn			
	165	170	175
Ile Pro Leu Ile Leu Glu Glu Leu Arg Val Leu Gln Gln Arg Gln Ile			
	180	185	190
His Gln Met Gln Met Thr Glu Gln Ile Cys Arg Gln Val Leu Leu Leu			
	195	200	205
Gly Ser Leu Gly Gln Thr Val Gly Ala Pro Ala Ser Pro Ser Glu Leu			
	210	215	220
Pro Gly Thr Gly Thr Ala Ser Ser Thr Lys Pro Leu Leu Pro Leu Phe			
225	230	235	240
Ser Pro Ile Lys Pro Val Gln Thr Ser Lys Thr Leu Ala Ser Ser Ser			
	245	250	255
Ser Ser Ser Ser Ser Ser Ser Gly Ala Glu Thr Pro Lys Gln Ala Phe			
	260	265	270
Phe His Leu Tyr His Pro Leu Gly Ser Gln His Pro Phe Ser Ala Gly			
	275	280	285
Gly Val Gly Arg Ser His Lys Pro Thr Pro Ala Pro Ser Pro Ala Leu			
	290	295	300
Pro Gly Ser Thr Asp Gln Leu Ile Ala Ser Pro His Leu Ala Phe Pro			
305	310	315	320
Ser Thr Thr Gly Leu Leu Ala Ala Gln Cys Leu Gly Ala Ala Arg Gly			
	325	330	335
Leu Glu Ala Thr Ala Ser Pro Gly Leu Leu Lys Pro Lys Asn Gly Ser			
	340	345	350
Gly Glu Leu Ser Tyr Gly Glu Val Met Gly Pro Leu Glu Lys Pro Gly			
	355	360	365
Gly Arg His Lys Cys Arg Phe Cys Ala Lys Val Phe Gly Ser Asp Ser			
	370	375	380
Ala Leu Gln Ile His Leu Arg Ser His Thr Gly Glu Arg Pro Tyr Lys			
385	390	395	400
Cys Asn Val Cys Gly Asn Arg Phe Thr Thr Arg Gly Asn Leu Lys Val			
	405	410	415
His Phe His Arg His Arg Glu Lys Tyr Pro His Val Gln Met Asn Pro			
	420	425	430
His Pro Val Pro Glu His Leu Asp Tyr Val Ile Thr Ser Ser Gly Leu			
	435	440	445
Pro Tyr Gly Met Ser Val Pro Pro Glu Lys Ala Glu Glu Glu Ala Ala			
	450	455	460
Thr Pro Gly Gly Gly Val Glu Arg Lys Pro Leu Val Ala Ser Thr Thr			
465	470	475	480
Ala Leu Ser Ala Thr Glu Ser Leu Thr Leu Leu Ser Thr Ser Ala Gly			
	485	490	495
Thr Ala Thr Ala Pro Gly Leu Pro Ala Phe Asn Lys Phe Val Leu Met			
	500	505	510
Lys Ala Val Glu Pro Lys Asn Lys Ala Asp Glu Asn Thr Pro Pro Gly			
	515	520	525
Ser Glu Gly Ser Ala Ile Ser Gly Val Ala Glu Ser Ser Thr Ala Thr			
	530	535	540
Leu Met Gln Leu Ser Lys Leu Met Thr Ser Leu Pro Ser Trp Ala Leu			
545	550	555	560
Leu Thr Asn His Phe Lys Ser Thr Gly Ser Phe Pro Leu Pro Leu Cys			
	565	570	575
Ala Arg Ala Leu Gly Ala Ser Pro Ser Glu Thr Ser Lys Leu Gln Gln			
	580	585	590

# COPY

Leu	Val	Glu	Lys	Ile	Asp	Arg	Gln	Gly	Ala	Val	Ala	Val	Thr	Ser	Ala		
	595						600					605					
Ala	Ser	Gly	Ala	Pro	Thr	Thr	Ser	Ala	Pro	Ala	Pro	Ser	Ser	Ser	Ala		
	610						615					620					
Ser	Ser	Gly	Pro	Asn	Gln	Cys	Val	Ile	Cys	Leu	Arg	Val	Leu	Ser	Cys		
625					630					635					640		
Pro	Arg	Ala	Leu	Arg	Leu	His	Tyr	Gly	Gln	His	Gly	Gly	Glu	Arg	Pro		
				645					650						655		
Phe	Lys	Cys	Lys	Val	Cys	Gly	Arg	Ala	Phe	Ser	Thr	Arg	Gly	Asn	Leu		
				660				665						670			
Arg	Ala	His	Phe	Val	Gly	His	Lys	Ala	Ser	Pro	Ala	Ala	Arg	Ala	Gln		
				675			680							685			
Asn	Ser	Cys	Pro	Ile	Cys	Gln	Lys	Lys	Phe	Thr	Asn	Ala	Val	Thr	Leu		
	690					695					700						
Gln	Gln	His	Val	Arg	Met	His	Leu	Gly	Gly	Gln	Ile	Pro	Asn	Gly	Gly		
705					710					715					720		
Thr	Ala	Leu	Pro	Glu	Gly	Gly	Gly	Ala	Ala	Gln	Glu	Asn	Gly	Ser	Glu		
				725					730						735		
Gln	Ser	Thr	Val	Ser	Gly	Ala	Gly	Ser	Phe	Pro	Gln	Gln	Gln	Ser	Gln		
			740					745						750			
Gln	Pro	Ser	Pro	Glu	Glu	Glu	Leu	Ser	Glu	Glu	Glu	Glu	Glu	Glu	Asp		
			755				760							765			
Glu	Glu	Glu	Glu	Glu	Asp	Val	Thr	Asp	Glu	Asp	Ser	Leu	Ala	Gly	Arg		
	770				775						780						
Gly	Ser	Glu	Ser	Gly	Gly	Glu	Lys	Ala	Ile	Ser	Val	Arg	Gly	Asp	Ser		
785					790					795					800		
Glu	Glu	Ala	Ser	Gly	Ala	Glu	Glu	Glu	Val	Gly	Thr	Val	Ala	Ala	Ala		
				805					810					815			
Ala	Thr	Ala	Gly	Lys	Glu	Met	Asp	Ser	Asn	Glu	Lys	Thr	Thr	Gln	Gln		
			820					825						830			
Ser	Ser	Leu	Pro	Pro	Pro	Pro	Pro	Asp	Ser	Leu	Asp	Gln	Pro	Gln			
		835					840					845					
Pro	Met	Glu	Gln	Gly	Ser	Ser	Gly	Val	Leu	Gly	Gly	Lys	Glu	Glu	Gly		
		850				855						860					
Gly	Lys	Pro	Glu	Arg	Ser	Ser	Ser	Pro	Ala	Ser	Ala	Leu	Thr	Pro	Glu		
865					870					875					880		
Gly	Glu	Ala	Thr	Ser	Val	Thr	Leu	Val	Glu	Glu	Leu	Ser	Leu	Gln	Glu		
				885					890					895			
Ala	Met	Arg	Lys	Glu	Pro	Gly	Glu	Ser	Ser	Ser	Arg	Lys	Ala	Cys	Glu		
				900					905					910			
Val	Cys	Gly	Gln	Ala	Phe	Pro	Ser	Gln	Ala	Ala	Leu	Glu	Glu	His	Gln		
				915				920						925			
Lys	Thr	His	Pro	Lys	Glu	Gly	Pro	Leu	Phe	Thr	Cys	Val	Phe	Cys	Arg		
						935						940					
Gln	Gly	Phe	Leu	Glu	Arg	Ala	Thr	Leu	Lys	Lys	His	Met	Leu	Leu	Ala		
945					950					955					960		
His	His	Gln	Val	Gln	Pro	Phe	Ala	Pro	His	Gly	Pro	Gln	Asn	Ile	Ala		
				965					970					975			
Ala	Leu	Ser	Leu	Val	Pro	Gly	Cys	Ser	Pro	Ser	Ile	Thr	Ser	Thr	Gly		
			980					985						990			
Leu	Ser	Pro	Phe	Pro	Arg	Lys	Asp	Asp	Pro	Thr	Ile	Pro					
			995				1000					1005					

<210> 2

<211> 16080

<212> DNA

<213> Homo sapiens

COPY

<400> 2

atatcacacc	ccagctggct	atgtaatcat	gaaataagga	gaaacacata	aatatttggg	60
taaaacacct	ttaatgatag	agggaaagac	actaatatct	cccgtctgtt	cttgacattt	120
tactaggtta	ggaagctctg	gagcctacag	cttgaggaga	agccatcgtt	caagtcagtc	180
aatagcaaaa	ccctcaactc	ctcctcctca	gaactcctgt	tccaaatgat	cctatgttaa	240
gagtaaatac	tacaactcat	tacaagacgg	agaggcaggg	aggacgccac	ctggagctgg	300
gactcttaag	aaccagacaa	tgacaaagac	acaagcccca	gcctacggat	aggcaaaatg	360
ggtaggggtc	ttgaaagagg	aagataagga	aaatacaagg	ggccagggaa	taaaggaggg	420
agttatctaa	aactagaagc	atactagtgc	taggaaatcc	cccatgatcc	ctggtacacc	480
tctgcacact	atgtcactat	tagcccaaaa	gaatattaac	gagaatgtcc	acattcacia	540
gaatttgagg	ccttttccct	tacatcatgt	ccctttctta	gtcacatagg	taccagcaag	600
ccctatgttc	tagcaacatt	ccttaactct	ctcatcatta	gttcatcaac	catgctgacc	660
aaaaatgttc	cttaaaagata	cgaacttcac	atttcccaaa	tatctcctgg	gagacctctt	720
ggcaagaaat	cagcttgttt	cccaactttg	agaggtcatc	atgaatgaga	agctggagag	780
gtcttggcac	actgaccagc	caaaaccttt	accttaatgt	gaccatcagg	ggatttactg	840
ggaaaatttt	cctatgccct	tccttcattt	ctccctactt	cctaggggtg	ggtcaccaat	900
tactggagca	tcttcagtac	cggcaccttc	tggagcaggg	ggaggaagaa	ggaatgtaca	960
gtttgtact	tcttgtctat	gatgggcttc	tcaggcactg	ccttgggtgc	aggaggctga	1020
aataggaggg	gggctgtctt	ctccttggct	tccttggatc	ccattgttgg	aggcaccttc	1080
ccaggccagc	ttcctaggcc	aaacagcact	ggtggggcca	ggcttggagt	ggtagtggag	1140
gtggagctgg	aattccaggg	cttcatgggc	aggccatttg	acaggaatgc	gcatactggg	1200
ttctagaaag	ataggggacc	catacccacc	agctgagcag	aaaggtcacc	ccagaggagt	1260
ggcactgggc	cctccagaga	cagctgccag	cccttttttg	ctaggctgca	atgccaaatg	1320
taggtgctca	ggtgcaccta	ccaaagggaa	agggagagga	gagaggaggg	ggaagaaggg	1380
tcacaccagg	gaagctggag	agggttcccc	ttgagaaagc	tgacagagaat	ctatgttctt	1440
caggtacaaa	gaatgaggag	ggaagaaaaa	ttccttaggg	ggccatcccc	ttgtaagcac	1500
agtaatttcc	aagctcaggg	actacagaaa	agccactagg	gacataacat	gttaagaact	1560
tagagaaaaa	gacaaaatca	gggtctataa	ctctgggagg	tccttttttg	aagctgtttc	1620
tgctctgtgg	gacaaagagc	agcagggtaca	gaaaaacagg	ctcatgggat	cgtgggggtca	1680
tcttttcggg	gaaaggggga	gagccctgtg	gaggtgatgg	aaggcgaaac	gccagggact	1740
agagaaagag	cagcaatatt	ctgagggcca	tggggggcaa	agggctgtac	ctggtggtgt	1800
gccaggagca	tatgcttctt	gagggtagcc	cgctcaagaa	agccctgcct	gcagaaaaca	1860
caagtgaaga	gcggcccttc	cttgggggtg	gtcttctgat	gtcctccag	agctgcctgg	1920
gagggaaagg	cctggccaca	cacttcgcag	gcctttctgc	tgctgtcttc	tcctggctcc	1980
tttctcattg	cctcctgcag	gtcagctcc	tctaccaagg	tcacgctgg	ggcttcccct	2040
tctgggggtga	gtgctgatgc	cggacttgag	cttctctccg	gtttgcccc	ctcttccctg	2100
cctcctaaaa	caccactgct	tccttgcctc	attggctgag	gctgatccag	gctgtcaggt	2160
ggtggtgggtg	gtggcaagga	agactgttga	gtagttttct	cattactgtc	catctccttc	2220
ccagctgtgg	ctgctgccgc	cactgtcccc	acctcctcct	ctgccccaga	tgctcttctt	2280
gaatcacctc	tactgatata	tgcttcttca	cctccactct	ctgagcctct	ccctgccagg	2340
gaatcttcat	cagtcacatc	ttcctcttct	tcctcatcct	cctcttccct	ctcctcagac	2400
aactcctctt	ccggtgatgg	ctgctgggac	tgctgctggg	ggaaactccc	tgccccggag	2460
actgtagatt	gctcggagcc	attctcctga	gcagctcctc	caccttcagg	gagtgcagta	2520
ccaccgttgg	ggatctggcc	ccccagggtc	atccggacat	gctgctgcag	agtgcacaga	2580
ttggtgaact	tcttctggca	gatggggcag	gaattctgtg	cccgggcagc	tggaactggc	2640
ttgtggccca	cgaaatgtgc	acgcagatta	cccctggtgg	agaaggctct	gccacacact	2700
ttgcatttga	agggcctctc	acctccatgt	tggccataat	gaaggcgtag	ggcccagagg	2760
cagctaagca	ctcggagaca	gatgacacac	tggttaggtc	cagaagaggc	tgaggatgaa	2820
ggtgcagggg	cagagggtgt	gggggtcctt	gaggcagctg	aggtcacccg	cacagctcct	2880
tgccgggtcaa	tcttttctac	cagttgctgc	agctttgatg	tctcagaggg	tgaggccccc	2940
aagggtctta	gcacataggg	gaagggggaa	ctgccagtgg	acttgaagtg	gttggtaagc	3000
agtgccagc	ttggtagtga	agtcaccaac	ttacttagtt	gcatgcgagt	tgccgtgcta	3060
ctttctgcca	ctccactgat	ggctgagccc	tactccctg	gggggggtgt	ttcatcagct	3120
ttattcttgg	gttccactgc	tttcatgagc	acaaacttat	tgaagcagg	gagtcctgga	3180
gccgtggctg	tgctgcact	ggtggagagc	agagtcaggc	tctctgtggc	actgagtgtc	3240
gttgtggagg	ccaccagagg	cttgcgctca	accttccac	ctggagtggc	tgccctcttc	3300
tcggccttct	ctgggtggac	ggacatacca	taaggcaagc	cactgctggt	aatgacatag	3360
tctaggtgct	ctgggtactg	gtgtgggttc	atctgcacat	gtgggtactt	ctcacgatgc	3420
cgggtggaat	gcactttgag	gttgccacgg	gtggtaaaac	ggtttccaca	gacattgcac	3480



ttatagggcc	tctcaccgct	gtgggaacga	agggtgatct	gcagggcact	gtcactgcc	3540
aatacttttg	cacagaagcg	gcatttgtgc	cttccaccag	gcttctccaa	gggacccatc	3600
acttctccgt	agctcagctc	accacttcca	ttctttggct	tcaggagccc	tggggaggca	3660
gtggcctcaa	ggcctcgggc	tgccccaa	gactgtgctg	ccagtagtcc	cgtggtgctt	3720
gggaatgcc	gatgaggcga	ggcaatcagc	tgatctgtgc	tgcctggcaa	ggctggggaa	3780
ggggcagggg	tgggtttgtg	gcttcgcccc	accctccag	cagagaaagg	atgctgtgac	3840
cccagtggtg	ggtaaagggtg	gaagaaggcc	tgcttgggcg	tttctgcccc	tgaagaggaa	3900
gaggaggagg	aggaggaaga	tgccagtgtc	ttgctgggtt	ggacaggctt	gatgggctg	3960
aagaggggta	gtaggggctt	gggtggaagag	gcagtccttg	tcccaggtag	ctctgaggga	4020
ctggcagggg	caccaccgct	ctggcctaag	gagccaagca	acagcacctg	cctgcagatt	4080
tgctcagtc	tctgcatctg	atggatctgc	cgctgctgca	gcacccgtag	ctcttccaag	4140
atcaggggga	tattcaagtg	gccactgcct	accctggggg	gcggaggggg	tgggtggagg	4200
ggagggggtg	caggggtcga	ttctggaggt	aatggggttg	ctcccagctt	gggactggcc	4260
aagatcagcg	ccccgcctcc	cccagccgct	gtacctgtgg	cagcgaccag	gaaatgccct	4320
ggagactcct	ctcctctcct	ctctgggccc	caggtgggat	ccgtgggcac	ggaggaccca	4380
gaatctgggg	ggttgctatg	ctctgtgtcc	atgacctgag	gattattgtg	accctcaggc	4440
cggggttcag	aggaggccga	agagttgttg	gggttctcct	ggcccccaat	tatcaccatt	4500
acaggagggg	cagtagaaca	tgcgttcttg	tggcgaggga	attcagttgg	gtcagtgaa	4560
tgtgcgcagc	acttggcaca	gacttggggg	tgatcctcct	cgctagcatc	acctggggag	4620
aagacaagga	gagagagcgt	gggtggcgca	gttgggttgg	gtataccgag	gctctaatta	4680
acaaggaggc	cagtaaccgc	tagttggggg	tggggagatg	agctcaccat	caggggccatg	4740
cagaagtcta	gagctcaggc	ctgatccgtg	tggacaggag	acaaccgggc	atggggcagg	4800
ggggtgggga	gggaggaggg	gaggggggca	agagcatgct	actccctccc	tcagccaccc	4860
tcccttcccc	aggccacaag	cgagttcacg	gaatagggtg	ggggacaggg	gcctacgcag	4920
agaatcatgc	attttctccc	accacccgaa	agtcttcgcc	gcccctgcgc	atccccctcc	4980
gccccacccc	ctgcccagcc	cgaccgacct	taccgcacct	ccgagctctg	ccggctcccc	5040
gcaggcgacc	ccgagacgag	agctcctctc	ggattcgtgc	gccatggttg	tgggggaaagt	5100
ggagggccag	gtgggggtggg	agacaatgga	tattgggatt	gagggaggcg	atggccgctg	5160
ggtctgcggc	agcctctgca	cccagcggcc	cagactgcgg	agatggagat	cggcagcggc	5220
gggggcaggg	agcagcggcg	gagggggagg	ggagcgaggga	ggcggggaga	agctggagtg	5280
agaaagcggg	gagaggggag	atctgggagg	agctgatgag	gaggggagtt	tatggggagg	5340
agctgctggg	gagggaggcg	ggagctagag	gagggggagg	aagggagcgc	tagcgggggc	5400
gtggggggcg	gagctcagag	ctcgggagag	tttccggagg	cgcagtgaca	ggtgctgtga	5460
agcactgcgg	gggtccacct	ttcccggtcc	ctggccagct	ccccccatct	gcagatgcct	5520
ttgcccaggc	ctaccctcct	ccccccgccc	tcccctccta	agctctaggg	gcacagtggg	5580
aaacgtagcc	ctgctcagtg	gagcaaggcg	ataggcttct	cttatttttc	tttgataaaa	5640
ggatccgctg	agcttggaaa	aagtggattc	cagagagggt	cgtctgatct	cctcagaggt	5700
ctgagggcca	gaagaagagg	gggagatcag	aacatccact	cctcaccagc	acacacaccc	5760
caaaaatattc	gaagttttgt	ctcgtctttc	tcacttccat	tcccacccta	cccccatccc	5820
tctccacaaa	agaagtttct	caggggtgggc	ggctgcaagg	tagaatttcc	caggaagtca	5880
tttcaggact	ctctgcggaa	cactaagccc	cttactccc	cgccccctct	ccccctgaat	5940
aatagctgaa	tgcaggttac	tccgcagatc	gccacgccta	cacaacacct	aattcataga	6000
gtccatgctt	atthaataag	ccatctccta	tttagtaccc	tcttctcctc	ctattctcct	6060
cttgcaacat	tcctcacacc	gtcactatta	aagacagtgg	gtttggggag	acgctagcct	6120
gcagaggcct	acggaggccc	accagctct	aacctggggg	ggaggggagc	cctcttgaaa	6180
caatgcggta	ggaactacca	ggcagccctc	agtgtctaaa	gccctttcag	ccccagcctg	6240
atltgaatgc	ttagaaatag	ctaacacctg	ctcaccatca	cagaggcagc	ctcctattca	6300
gacaggataa	gtaagaataa	aatgcctcct	ggaccaggta	ttctggcatt	ctctttttta	6360
ccttgaaatg	agtcttaaa	tgttccccc	ttcctaaaa	actttctctt	acatgcagga	6420
agtgaccaca	agtccttggt	tttgtgggtt	ccctgggcat	cagtaaacct	aaattgtttt	6480
aatccccagtt	ctattcttgc	ctcactgata	aaactgagac	atggtggtca	gtcacacct	6540
gttataccac	cgtttccctc	ttcataaagt	ggtaaatattg	tagctgcagt	atthttactca	6600
gaaaaatatt	gtggggacaa	aaaattgaaa	aattggacaa	tattaatgtg	taaaccaggt	6660
atggtgggtg	acacttgtag	ccccagctac	ttgggaggct	gaggcaggag	aattgcttta	6720
gtccaggagt	ttgaggctgc	agtgaagctg	gatcacacct	gtgaataacc	actgccctcc	6780
agcttcggca	acatagttag	gccccattac	tttaaaaaaa	aaaaaaagcc	gggcggcggtg	6840
gtcactgta	atcccagcac	tttgggaggt	gggcagatca	cgaggtcaga	agttccagac	6900
cagcatggcc	aacatgttga	aaccccgctc	ctactaaaaa	tacaaaaatt	agctgggcat	6960
gatggtacac	ctttaatccc	agctactggg	gcagctgagc	caggagaatg	gcttgaaccc	7020

COPY

aggaggtgga	ggttgagg	ggctgagatc	gtggcattgc	actccagcct	gggcaacaag	7080
agtgaactg	cgtctcaaaa	aaaaaaaaaa	gtctaaaaaa	attaatatgt	acatgtgaga	7140
tttttaaagt	ttggggagtc	ctgaatttaa	tcaatgagat	aatttacatt	gtcagtagca	7200
aaataatcga	agtaacctta	aatacacata	tactaaaatt	agatctgttt	tccatgttgt	7260
ttgttaatct	tattaatttc	tgaggtaaga	tattggctaa	tatcagcagc	atatttcaaa	7320
ggtaggaagt	cttttattgc	agtgggtggg	ggagctgaaa	caacctatct	aaaatattag	7380
taacatccac	tttactttc	aacataaatt	ttgctgtgt	ttttaaactt	aaaacagttt	7440
actgaattat	gttttgaaac	ttcagataat	aaggctctta	gcattgtgag	tcataattct	7500
gaaatggacg	ggttctgtgc	ttccaggcct	ggacttacaa	atgagggagg	ggggttctat	7560
ttcagtttat	ggcaagtcac	agttttgtgc	aatgtggttt	atttttacag	ataaggaaac	7620
tgaagcttgg	agaggttaag	tgacttttcc	aagttcacac	agtaattcag	tgaagcaagc	7680
attcagaatt	ttgactcctg	tccaatgctt	tctcaagcac	atcaactttg	tatggcttcc	7740
ctaagtctag	agaaagggcc	ctgtgtggct	tctacctgcc	atgtgtctcc	tggccttagt	7800
caggagagag	gaatcagatg	gaggctttct	actgagcatt	tgtaatttag	cattgaacat	7860
ttgatattca	gttgctgttt	tgtcaagtct	tctgacaaga	aaagaaatcc	ttttcttttc	7920
atcttctcct	gggaaacact	gtcccccttc	ttgctcttta	atgaaatgtg	ctttctgatg	7980
cgtaatttga	tctaagctct	tctttaaggt	aaatttagtc	cctgggtgaa	ggtgactgga	8040
tcaacagcca	cctgtaagag	gaaccctcca	tttctcagta	ctttgcactc	actgcacatc	8100
ctgaaaagg	gggcaggatt	cttacacaaa	catgaatgaa	gtcacaaatg	caggaataaa	8160
ctaaactggt	aatggtgtcc	ctagatagca	gataaggtga	ggtaagctat	ctccggtcaa	8220
atgcaaagtc	cgggggtgga	ctaagacctg	gacaagcttg	tttaaaactta	tagagagctg	8280
aaatgacaaa	gaaaaggga	accaggtggc	ttcccttcta	aatctagtgt	cccatcagat	8340
tgcttcttta	ggcttcagag	agaactgttc	gggagaacaa	agagaaaaat	aggtgagttg	8400
tatgtagcag	ggtgatacat	ttgaacagcg	gttttcaaat	tttgctgcc	attaggatta	8460
ccagaagaga	gttttaaaat	ttttatgttt	aggtgcagtg	gtctgttctc	tgtagtccca	8520
gctactctgg	aggctgaggc	gggaggatca	cttagctca	agggtttgag	actccatctc	8580
aaaatctcaa	aaaaaagaag	aaaaaaaaaa	gaaaagaaag	tttaagcaca	gtgggtacct	8640
catgcctata	atcctagcac	ttttggaggc	caaggcagga	ggattgcttg	aggccaggaa	8700
tttgagacca	gcctgcataa	catagtgaga	cccccatctc	tgcaaaagca	accaaccaac	8760
caaacttaaa	aaaaatccct	gtgtccaggc	cacatcccag	gctaattaat	tcataatccc	8820
tgaggatagg	atccaggcat	tagtttgata	aagctcctca	ggtgattcca	atgagaatac	8880
aaagatgggt	acacaatgat	gagaccacac	tggaggactg	ccctttccat	cataccttcc	8940
accctgctcc	tcacagatct	tacctgagct	aaacttgccc	acaattggga	cacagacaaa	9000
atgaactctc	aatgctaaat	cttcccatca	ggtccctctc	ctacagtgcc	cacaaccaca	9060
cattaacttc	cttgtatcct	ttcccagtg	aaaatctgct	tccatgaata	gaatttgata	9120
taatttacac	cttactgtaa	gtttaagtga	ttgcatttct	ttcccaggta	tgggtatctt	9180
gaagcatatt	tttttctttt	ttaattgata	tttgagccat	atttcttttt	ttttcttttc	9240
tttttttttt	tttttttttt	ttgagacgga	gttttgtctc	cattgcccag	gctggagtgc	9300
aatggcatga	tctcggtcca	cgcgaacctc	cacctcccag	gttcaagcga	ttctctgtcc	9360
tcagccttcc	caagtagctg	ggattacagg	catgtgccac	caagcccggc	taattttgta	9420
tttttagtag	agatgggggt	tctccatgtg	ggtcaggctg	gtctcaaact	cccgaacctc	9480
ggtgatctgc	caacctcggc	ctcccaaagt	ggtgggatta	caggcgtgag	ccatcgcgcc	9540
cggccaccat	atttctaatt	gtaagggtga	aggctttggt	ctacagagtt	caagcatcat	9600
ccaccattta	aggctggagt	gaagtggcac	aatcatagct	cactgcagac	tctacctccc	9660
aggcttaggt	gatcctccca	cctcagcttc	ctgaatagct	gggactacag	gcatgcacaa	9720
tcatgcccag	ctaattaaaa	tatttttttc	tgtagagatg	aggtttctact	atgttgccca	9780
ggctgtctgg	aatacctggg	ctcaagggat	cctcctgcct	tgtccccaca	aagtgtgag	9840
agtacagatg	taagccactg	cctctggccc	acttacttat	tattgacact	gaacaatgct	9900
aattggtagc	ttccataatt	atgaattgat	tctgtaacta	ttgctactga	ctacttctta	9960
gggaaataac	tcatcttttc	ctccttactc	ctctttccta	aatgtagaca	cataataatc	10020
ctttgcaacc	cgacacctact	aatgtaacta	tggcctatgt	aacacagtag	actaacaggc	10080
acaatgattg	gtacacctgg	tgctaagtga	gaaaaagata	tttgtttcca	gaacagggaat	10140
atcttagatc	aaacataaga	atgttctttt	aatgaaaatt	tctttgactt	caaaggactc	10200
aacacttaac	atggaattca	taccattttg	gagctgggac	ttcagagatc	tgacactctc	10260
attgtcattg	tgcacagtga	ttcagacctg	agttaaagtc	ccagctctag	aacattctaa	10320
tattttgtat	cttgggaaaa	ttctttaate	tctcccagag	ttgtttttct	tatttttttt	10380
tgggacagag	tttcaactct	gttgcccagg	ctggagtgc	atggcacgat	cttagctcac	10440
cgcaacctcc	gcctcccagg	ttcaagcgat	tctcctgcct	cacctccct	agtagctggg	10500
attacaggca	tgtgccacca	cgcccggtca	attttgtatt	tttttagtag	agacgggggt	10560

# COPY

tcttcatatt	gctcaggctg	gtctcaaact	cccagcctca	ggtgatctgc	ccacctcggc	10620
ctcccaaagt	gctggattac	aggcatgagc	caccgcgcct	ggccagcctt	ttttttttt	10680
ttgagacgga	gtctcgctct	gtcgccagg	ctggagtgc	atggctcgcc	aggctggagt	10740
gcaatggtgt	gatctcggt	cactgcaatc	tccgcctcct	gggttcaaac	gattttcctg	10800
cctcagcctc	ccaagtagct	gggattacag	gtgtgcgcca	tcacaccag	ctaatttttg	10860
tatttttagt	agagatgagg	tttcaccttg	ttggccaggc	tggctctgaa	ctcctgacct	10920
caagtgattt	gcccacctca	gcctcccaaa	gtgctgagat	tacaggcatg	agctgctgtg	10980
ccggctgat	ttctcttctt	taaaatgagg	gtactgccat	acaaaggaag	gaaattctga	11040
tacatgctac	aacatgaatg	aactttgtaa	acattatgct	ttcagacaaa	tttgacttta	11100
attgagaaaa	aaagagaaaa	catactaagt	gcaataaagc	agacacaaaa	ggacaaatat	11160
tgtatgattc	cattagtagt	aggtacccaa	acattatatg	agtccattaa	tatgaaattt	11220
ggcaagggtca	cacatacaga	aagcagagta	gaggctaaca	gggctaaggg	aatgggagaa	11280
tggggattta	ttgtttaacg	gttacagttt	ctgtttgatg	atgaaaaaga	tattgaaaca	11340
gcagtaatgg	ttacataaca	tagtgaatgt	acttaatgcc	actgaattgt	acacttaaaa	11400
atggttaaaa	tggtaaat	tattacacat	attttacaat	aaaaaaattt	tagccaggtg	11460
tgggtggcatg	cacctgtaat	cccagctgtt	caggaggctg	aggcaggaga	atctcttgaa	11520
ccctggaggt	ggaggtttca	gtgagccgag	acgtgccact	gcactccagc	ctgggcaaca	11580
gagtaggact	tgggtctcaaa	aaaagaaaaa	aatttttttt	gtaataataa	gggagtggg	11640
gctgggctg	gtggctcacg	cctgtaatcc	cagcactttg	ggaggccaaa	gtgggcggat	11700
catgaagtca	ggagatcgag	accatcctgg	ctaacacagt	gaaacctgt	ctctactgaa	11760
aatataaaaa	attagccagg	tgtggtggcg	ggcgctgtga	gtcccagcta	cttgggaggc	11820
tgaggcagga	gaatggtgtg	aacccgggag	gcggagctcg	cagtgcgcca	agatcgcgcc	11880
actgcacccc	agcctgggag	acagagcgag	actccgtctc	aaaataataa	aaataaataa	11940
ataaataaat	aaaataataa	taataacgga	gttgggagga	aaaagaggaa	atgcaaaaag	12000
ggcctagcac	agtacctgaa	tgctccacaa	atattagcca	tgggtgttag	ttattatttg	12060
aatgtcaaaa	gctgaatgaa	gccttggggt	aagaaaggct	acatgtgccc	aaggtcacat	12120
agcttcaagg	tccacactag	attgaaaacc	aagttttctg	ttttcttctc	tagtactctg	12180
taacaccagg	actgagatac	tctctattcc	aaaatgtgtt	ttttctgata	tgggaatacc	12240
taggttgagt	ggcccaggga	tcaataacct	gagagatgag	gctctttact	tccaaatgta	12300
aacagagccc	ccaaaactct	acctttgcct	tctttcctct	cttgcctgtc	ttgctatctg	12360
ccaacttcca	tctaaagtac	tcccctctct	ccctctagat	ctgtttggct	gctgtcctgg	12420
tttcttcttc	tcaactaaata	tctgggtttc	tgattgtttc	ctttatttcc	cagatgtact	12480
ggtttgcatt	tttccccag	tcacatcctt	tgtgttctct	aatccagatt	tctagactct	12540
gtaggggaga	gagaagggtt	ttttttttcc	tctctagagt	ttttaagtga	atagagtatt	12600
tctgccccat	cacttatatg	caataactgt	tctgttaggt	tttgatgctc	tgggtaggga	12660
agctgagcaa	aaacggctgg	aaaacagatt	tttcagactg	tttcttggtg	atgtcttagg	12720
tactgcaga	attttggtct	ttaaaatatg	taacaaaggc	tcagcatttg	catgttgtat	12780
atggcacata	ttgcttacaa	gaaggcaaaa	gactcctgga	aacattactg	gcaccctaga	12840
ctactgacta	aatgtcttct	gatactcatg	atgatatcca	taatttcaca	ggtacaccaa	12900
aggatacatg	tgcccctaaa	taagagccct	tccctccctaa	ctgtggagca	tgctctgggg	12960
tagaagggaag	tcagatgcct	gaagatcaca	taagtgaata	gaaacctgt	ctataaaaaa	13020
ttagggaaaa	ggagagctct	cattctgttt	tgcagaatgg	atgctgcccc	attcatgatt	13080
aagaaaattt	attaatttaa	aagaaaacca	gaaaatgtga	aatttatata	ttataagctt	13140
ataagatcca	ggaggaattt	tagatacgat	caaatagagc	cacctcattt	tgcatagtag	13200
gccaatgac	atccagatca	taagtgcct	aggatctttc	actccagggg	aattctgatg	13260
agaaaatcct	taggctttct	tacggtagat	cttaacagag	ggtgctactg	cttctctgct	13320
ccttacattt	gttctctgct	ttcatagctc	aaaggcaaat	tttcatcaaa	aatttggtga	13380
tgccattggg	tttaaacctt	tactgtttct	atggggatgg	ctttgtaaca	gcattaccat	13440
gccccagggt	ggaagctata	tcttaaaggg	cttgaaaatc	cattcaagac	agccgctaaa	13500
gatagctttt	gactccctca	cagaagattt	ttcctcagct	atgatatggg	gaatgggtga	13560
gcagatggga	gaagtaggaa	gaagaggaga	gaatgcttct	tgggggtttg	gaggggtgtt	13620
cagcatagtt	ccacaatcaa	accagcagga	gagcagaact	gtgaggcaac	tctggggagg	13680
agttgaggct	ctaggggaag	tctcctgtag	agcacaagca	ggaaacatcc	ggcctatagc	13740
agcatthaaga	agggctaatt	tgtctcagga	gggaaggatg	ccatcaccat	agaacctcta	13800
aatatgggca	cagtaggatc	ccagaaaagc	agtgtttcgg	ggaggatgag	ttctgccccaa	13860
aacatgtctg	ttaaggttat	ttttagtcac	atggagcgct	gatttgacct	caagtttttg	13920
ttttttaaca	ggtggaagg	caagtttaat	ctacaatttt	agtcgccacc	aatacactct	13980
cttagagctt	ttcatgacac	gtctcataaa	gaaatgctga	tggccgggag	cgggtggtca	14040
cgctgtaat	cccagcactt	tgggaggcca	aggcgggag	attacgagat	caggagatcc	14100

# COPY

```

agagcatcct ggctaacacg gtgaaacccc gtctctacta aaaatacaaa aaattagccc 14160
ggcgtggtgg caggcgccta tagttccagc tactcgggag gctgaggcag gagaatggcg 14220
tgaacctggg aggtggagcg ggcagtggag caagattgca ccactgcact ccaacctggg 14280
cgacagagcg agactctctc tcaaaaaaaa aaaaagaaaa aaagaaaaag aaaagaaaag 14340
aaaaaaaaag aaatgctgac gtttgccaag aggttcctga gttttggtca tactacagca 14400
cttgacagca gtgtcactgc attcacatat aatgataata acgatattca cacatattaa 14460
gcacttattt atgctaggta tttttccaag ggatttacac atattaactc atttagattt 14520
tcacaacaac ctaatgaggt agctagtata cacatcttta tttcacagat gaggaaactg 14580
aagcatagag aggcaaaaata aaccagccaa ggtcacatag ctaaccaagt ggtggagctg 14640
ggatttgtct aaaagtctgg tttcagaacc cttgtgctta atcctatact atactgttg 14700
gtgtatcaac tgtatgctaa acagtgcct gtctggagcc aggacttcca gactttcagt 14760
ctgcacatat ggagccatac cactgacaag tatgtccaaa acttctttga tcctaagaat 14820
tacctggaca attgcaaaaat atatagattc ccacaccctg gctcagatgt actcacaatc 14880
aggcaagttt ttaaaaccca ggtttagtgg gtttagtgag cactaccagc cagccctgag 14940
cattaggaaa ttgaagtttt tgtcctgatt ttgcttctgt ctctcagact ctgagcaatt 15000
tcaactttca attccctgct tgctctactg tctgctgtc acttaacgga atgttacaag 15060
aatacataca atttttcccc ctcataaggg acacctgttg cttcaaaaac acggtatcct 15120
cataaaatga tatgcatgta gtaacagggtg tattttcttg cacttctttt gttttgtttt 15180
gttttttgc tttgctttct tgaagcacia acctaagccc ctcatccaga cctagccttc 15240
agctgtcttc caggtgacac gcatacacac cccaaaccag gctgcattct gaccgacctt 15300
agctctctcc ctctgggagc tctgatcggc tctcagttca gccaacaat gagaaacttt 15360
tttctcgtct ccctcagggg agccttcacg tttatccaat tcattctctt gcaaccaaac 15420
tctccagaaa gaaaaggggg gaaaatccca ccccgagag acggtcttca ggtctgagga 15480
cgttacttag caacggcaca aagaccagtg agcaaaggga gacctgagga gaaaactctt 15540
gggtggggag acagagccag tttgaaaact ccatttcac cagagaaaaa caaggaaaac 15600
acaaacagaa tcaatcccaa gtaacaagcg gggcttctcc ccagcgcagg tcactcttta 15660
ctccctgcat ctcaactcct tcaaaccccc agtgaccaag tccgcccccg cctggttctg 15720
cccatggccc gagtgccctc cccttgccct ggctgaccc acacaggctt ggacttaggg 15780
gccccacccc ctccccaggc acccaccgtt ctgagacgag ctgggacctt cgcagtccga 15840
gattaactgt tgggggtttcc gctgcttctg ccgagacatt cccgggtaga gagttgggag 15900
agggaggggc aacgctcact tggctttaac cgggggtgac tgggtctctc tcccccttgg 15960
gtccgaagcc aattgatgcc tctccccag cgcaaatcac tgtgaagcag agatgttctt 16020
ctttccaga gacacagact ctctctctct ctctgattct ctgttcttga ctctctctct 16080

```

<210> 3  
 <211> 1002  
 <212> PRT  
 <213> Mus musculus

<400> 3

Met	Ala	Gln	Glu	Thr	Gly	Ser	Ser	Ser	Arg	Leu	Gly	Gly	Pro	Cys	Gly
1				5					10					15	
Glu	Pro	Ala	Glu	Arg	Gly	Gly	Asp	Ala	Ser	Glu	Glu	His	His	Pro	Gln
			20					25					30		
Val	Cys	Ala	Lys	Cys	Cys	Ala	Gln	Phe	Ser	Asp	Pro	Thr	Glu	Phe	Leu
		35				40						45			
Ala	His	Gln	Asn	Ser	Cys	Cys	Thr	Asp	Pro	Pro	Val	Met	Val	Ile	Ile
		50				55					60				
Gly	Gly	Gln	Glu	Asn	Pro	Ser	Asn	Ser	Ser	Ala	Ser	Ser	Ala	Pro	Arg
65					70					75				80	
Pro	Glu	Gly	His	Ser	Arg	Ser	Gln	Val	Met	Asp	Thr	Glu	His	Ser	Asn
				85				90						95	
Pro	Pro	Asp	Ser	Gly	Ser	Ser	Gly	Pro	Pro	Asp	Pro	Thr	Trp	Gly	Pro
			100					105					110		
Glu	Arg	Arg	Gly	Glu	Glu	Ser	Ser	Gly	Gln	Phe	Leu	Val	Ala	Ala	Thr
		115					120					125			

# COPY

Gly	Thr	Ala	Ala	Gly	Gly	Gly	Gly	Gly	Leu	Ile	Leu	Ala	Ser	Pro	Lys
130						135					140				
Leu	Gly	Ala	Thr	Pro	Leu	Pro	Pro	Glu	Ser	Thr	Pro	Ala	Pro	Pro	Pro
145					150					155					160
Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Gly	Val	Gly	Ser	Gly	His	Leu	Asn
				165					170					175	
Ile	Pro	Leu	Ile	Leu	Glu	Glu	Leu	Arg	Val	Leu	Gln	Gln	Arg	Gln	Ile
			180					185					190		
His	Gln	Met	Gln	Met	Thr	Glu	Gln	Ile	Cys	Arg	Gln	Val	Leu	Leu	Leu
		195					200					205			
Gly	Ser	Leu	Gly	Gln	Thr	Val	Gly	Ala	Pro	Ala	Ser	Pro	Ser	Glu	Leu
210						215					220				
Pro	Gly	Thr	Gly	Ala	Ala	Ser	Ser	Thr	Lys	Pro	Leu	Leu	Pro	Leu	Phe
225					230					235					240
Ser	Pro	Ile	Lys	Pro	Ala	Gln	Thr	Gly	Lys	Thr	Thr	Ala	Ser	Ser	Ser
				245					250					255	
Ser	Ser	Ser	Ser	Ser	Ser	Gly	Ala	Glu	Pro	Pro	Lys	Gln	Ala	Phe	Phe
				260				265					270		
His	Leu	Tyr	His	Pro	Leu	Gly	Ser	Gln	His	Pro	Phe	Ser	Val	Gly	Gly
		275					280					285			
Val	Gly	Arg	Ser	His	Lys	Pro	Thr	Pro	Ala	Pro	Ser	Pro	Ala	Leu	Pro
290						295					300				
Gly	Ser	Thr	Asp	Gln	Leu	Ile	Ala	Ser	Pro	His	Leu	Ala	Phe	Pro	Gly
305					310					315					320
Thr	Thr	Gly	Leu	Leu	Ala	Ala	Gln	Cys	Leu	Gly	Ala	Ala	Arg	Gly	Leu
				325					330					335	
Glu	Ala	Ala	Ala	Ser	Pro	Gly	Leu	Leu	Lys	Pro	Lys	Asn	Gly	Ser	Gly
				340				345					350		
Glu	Leu	Gly	Tyr	Gly	Glu	Val	Ile	Ser	Ser	Leu	Glu	Lys	Pro	Gly	Gly
		355				360						365			
Arg	His	Lys	Cys	Arg	Phe	Cys	Ala	Lys	Val	Phe	Gly	Ser	Asp	Ser	Ala
370						375					380				
Leu	Gln	Ile	His	Leu	Arg	Ser	His	Thr	Gly	Glu	Arg	Pro	Tyr	Lys	Cys
385					390					395					400
Asn	Val	Cys	Gly	Asn	Arg	Phe	Thr	Thr	Arg	Gly	Asn	Leu	Lys	Val	His
				405					410					415	
Phe	His	Arg	His	Arg	Glu	Lys	Tyr	Pro	His	Val	Gln	Met	Asn	Pro	His
				420				425					430		
Pro	Val	Pro	Glu	His	Leu	Asp	Tyr	Val	Ile	Thr	Ser	Ser	Gly	Leu	Pro
		435				440						445			
Tyr	Gly	Met	Ser	Val	Pro	Pro	Glu	Lys	Ala	Glu	Glu	Glu	Ala	Gly	Thr
450					455						460				
Pro	Gly	Gly	Gly	Val	Glu	Arg	Lys	Pro	Leu	Val	Ala	Ser	Thr	Thr	Ala
465					470					475					480
Leu	Ser	Ala	Thr	Glu	Ser	Leu	Thr	Leu	Leu	Ser	Thr	Gly	Thr	Ser	Thr
				485				490						495	
Ala	Val	Ala	Pro	Gly	Leu	Pro	Thr	Phe	Asn	Lys	Phe	Val	Leu	Met	Lys
				500				505					510		
Ala	Val	Glu	Pro	Lys	Ser	Lys	Ala	Asp	Glu	Asn	Thr	Pro	Pro	Gly	Ser
		515					520					525			
Glu	Gly	Ser	Ala	Ile	Ala	Gly	Val	Ala	Asp	Ser	Gly	Ser	Ala	Thr	Arg
530					535						540				
Met	Gln	Leu	Ser	Lys	Leu	Val	Thr	Ser	Leu	Pro	Ser	Trp	Ala	Leu	Leu
545					550					555					560
Thr	Asn	His	Leu	Lys	Ser	Thr	Gly	Ser	Phe	Pro	Phe	Pro	Tyr	Val	Leu
				565				570						575	
Glu	Pro	Leu	Gly	Ala	Ser	Pro	Ser	Glu	Thr	Ser	Lys	Leu	Gln	Gln	Leu
			580					585					590		
Val	Glu	Lys	Ile	Asp	Arg	Gln	Gly	Ala	Val	Ala	Val	Ala	Ser	Thr	Ala

# COPY

595					600					605					
Ser	Gly	Ala	Pro	Thr	Thr	Ser	Ala	Pro	Ala	Pro	Ser	Ser	Ser	Ala	Ser
610						615					620				
Gly	Pro	Asn	Gln	Cys	Val	Ile	Cys	Leu	Arg	Val	Leu	Ser	Cys	Pro	Arg
625					630					635					640
Ala	Leu	Arg	Leu	His	Tyr	Gly	Gln	His	Gly	Gly	Glu	Arg	Pro	Phe	Lys
				645						650					655
Cys	Lys	Val	Cys	Gly	Arg	Ala	Phe	Ser	Thr	Arg	Gly	Asn	Leu	Arg	Ala
			660					665					670		
His	Phe	Val	Gly	His	Lys	Thr	Ser	Pro	Ala	Ala	Arg	Ala	Gln	Asn	Ser
		675					680					685			
Cys	Pro	Ile	Cys	Gln	Lys	Lys	Phe	Thr	Asn	Ala	Val	Thr	Leu	Gln	Gln
690						695					700				
His	Val	Arg	Met	His	Leu	Gly	Gly	Gln	Ile	Pro	Asn	Gly	Gly	Ser	Ala
705					710					715					720
Leu	Ser	Glu	Gly	Gly	Gly	Ala	Ala	Gln	Glu	Asn	Ser	Ser	Glu	Gln	Ser
				725					730						735
Thr	Ala	Ser	Gly	Pro	Gly	Ser	Phe	Pro	Gln	Pro	Gln	Ser	Gln	Gln	Pro
			740					745					750		
Ser	Pro	Glu	Glu	Glu	Met	Ser	Glu	Glu	Glu	Glu	Asp	Glu	Glu	Glu	
		755					760					765			
Glu	Glu	Asp	Val	Thr	Asp	Glu	Asp	Ser	Leu	Ala	Gly	Arg	Gly	Ser	Glu
		770					775					780			
Ser	Gly	Gly	Glu	Lys	Ala	Ile	Ser	Val	Arg	Gly	Asp	Ser	Glu	Glu	Val
785					790					795					800
Ser	Gly	Ala	Glu	Glu	Val	Ala	Thr	Ser	Val	Ala	Ala	Pro	Thr	Thr	
				805				810							
Val	Lys	Glu	Met	Asp	Ser	Asn	Glu	Lys	Ala	Pro	Gln	His	Thr	Leu	Pro
				820				825							
Pro	Pro	Pro	Pro	Pro	Pro	Asp	Asn	Leu	Asp	His	Pro	Gln	Pro	Met	Glu
		835					840					845			
Gln	Gly	Thr	Ser	Asp	Val	Ser	Gly	Ala	Met	Glu	Glu	Glu	Ala	Lys	Leu
		850					855					860			
Glu	Gly	Ile	Ser	Ser	Pro	Met	Ala	Ala	Leu	Thr	Gln	Glu	Gly	Glu	Gly
865					870					875					880
Thr	Ser	Thr	Pro	Leu	Val	Glu	Glu	Leu	Asn	Leu	Pro	Glu	Ala	Met	Lys
				885					890					895	
Lys	Asp	Pro	Gly	Glu	Ser	Ser	Gly	Arg	Lys	Ala	Cys	Glu	Val	Cys	Gly
			900				905						910		
Gln	Ser	Phe	Pro	Thr	Gln	Thr	Ala	Leu	Glu	Glu	His	Gln	Lys	Thr	His
		915					920					925			
Pro	Lys	Asp	Gly	Pro	Leu	Phe	Thr	Cys	Val	Phe	Cys	Arg	Gln	Gly	Phe
		930					935					940			
Leu	Asp	Arg	Ala	Thr	Leu	Lys	Lys	His	Met	Leu	Leu	Ala	His	His	Gln
945					950					955					960
Val	Pro	Pro	Phe	Ala	Pro	His	Gly	Pro	Gln	Asn	Ile	Ala	Thr	Leu	Ser
				965					970						975
Leu	Val	Pro	Gly	Cys	Ser	Ser	Ser	Ser	Ile	Pro	Ser	Pro	Gly	Leu	Ser
			980						985						990
Phe	Pro	Arg	Lys	Asp	Asp	Pro	Thr	Met	Pro						
		995					1000								

<210> 4  
 <211> 4547  
 <212> DNA  
 <213> Mus musculus  
  
 <400> 4

# COPY

atggcgcagg	aaaccgggag	cagctctcga	ctcgggggac	cctgcgggga	gcctgcggag	60
cgcgagggtg	atgctagcga	ggaaacaccac	ccccaaagtct	gtgccaaatg	ctgcgcacaa	120
ttttctgacc	cgaccgaatt	cctcgctcac	cagaactcat	gttgactga	cccaccggta	180
atggtgataa	ttggaggcca	ggagaatccc	agcaactctt	cagcctcctc	tgcgccccga	240
ccagagggcc	acagtaggtc	ccaggtcatg	gatacagagc	acagcaatcc	cccagattct	300
gggtcctctg	ggcccccgga	tcccacttgg	gggccagagc	ggaggggaga	ggaatcttct	360
gggcaattcc	tggtcgctgc	cacaggtaca	gcggctgggg	gaggtggggg	ccttatcttg	420
gccagtccca	agctgggagc	aaccccatta	cctccagaat	ccactcctgc	accccctcct	480
ccccaccac	cccctcccc	tccaggtgta	ggcagtgggc	acttgaacat	tcctctgatc	540
ttggaagagt	tgcgggtgct	gcagcagcgc	cagattcacc	agatgcagat	gactgaacaa	600
atctgcgccc	aggtgctgct	acttggctcc	ttggggcaga	ccgtgggtgc	ccctgccagt	660
ccctcagagc	tacctgggac	aggggctgcc	tcttccacca	agcccctcct	gcctctcttc	720
agtcccatca	agccagcgca	aactggcaag	acactggcat	cttctctctc	gtcatcctcc	780
tcctctggag	ctgaaccgcc	taagcaggct	tttctccacc	tttaccatcc	actgggatca	840
cagcatcctt	tctctgtagg	aggggttggg	cggagccaca	aaccaccccc	tgccccttcc	900
cctgcgctgc	caggcagtac	ggatcagctg	attgcttcac	ctcatctggc	attcccaggc	960
accactggac	tcctggcagc	tcagtgtctt	ggggcagcaa	ggggccttga	ggctgctgcc	1020
tccccagggc	tcctgaagcc	aaagaacgga	agtgtgaac	tgggctatgg	ggaagtgatc	1080
agttccttgg	agaaacccgg	tggaaggcac	aaatgccgct	tttgtgcaaa	agtattcggc	1140
agtgacagcg	ccctgcagat	ccaccttctg	tcccacactg	gtgagaggcc	ctataagtgc	1200
aacgtctgtg	gtaaccgttt	cacaactcgg	ggcaacctca	aagtacattt	tcaccggcat	1260
cgtgagaagt	accacatgt	gcaaatgaat	ccacatccag	taccggagca	cctagactac	1320
gtcatcacca	gcagtgggct	gccttacgga	atgtctgtgc	caccagagaa	agcagaagag	1380
gaggcaggca	caccaggcgg	aggtgttgaa	cgcaaacc	tagtggcctc	caccacagca	1440
ctcagtgcc	cagagagcct	gacactgctc	tccactggca	caagcacagc	agtggctcct	1500
gggtccctta	ctttcaacaa	gtttgtgctc	atgaaggcag	tggaacc	gagtaaagcg	1560
gatgagaaca	cgccccagg	gagtgagggc	tccgccatcg	ctggagtgc	agacagtggc	1620
tcagcaaccc	gaatgcagct	aagtaagctg	gtgacgtcac	taccgagttg	ggcactgctt	1680
actaatcact	tgaagtcaac	tggaagtttc	cccttccctt	atgtgctaga	acccttgggg	1740
gcttcgcctt	ctgagacctc	aaagctgcag	cagctagtag	aaaagattga	ccgccaagga	1800
gctgtggcgg	tggcatctac	tgcctcgga	gctccacca	cttctgcccc	tgcaccttcc	1860
tctctcgctt	ctggacctaa	ccagtgtgtg	atctgtcttc	gggtcctgag	ctgcccctcg	1920
gctctacgcc	tgcattatgg	ccaacatgga	ggtgagcggc	ccttcaagtg	taaagtgtgt	1980
ggccgagctt	tctccacaag	gggcaatttg	cgcgcacatt	tctgtgggtca	caagaccagt	2040
ccagctgccc	gggctcagaa	ctcctgcccc	atttgtcaga	agaagttcac	taatgctgtc	2100
actctgcagc	aacatgttcg	gatgcacctg	gggggcagaa	tccccaatgg	gggttccgca	2160
ctttctgaag	gtgggggagc	tgcccaggaa	aacagctctg	agcagtctac	agcctctgga	2220
ccagggaagt	tccccagcc	gcagtcccg	cagccatctc	cagaagagga	gatgtctgag	2280
gaagagggaag	aggatgagga	agaggaggaa	gacgtgacag	atgaagattc	cctagcagga	2340
agaggctctg	agagtggggg	agagaaggcc	atatcagtac	gaggtgactc	agaagaggta	2400
tctggggcag	aggaagaagt	ggcaacatca	gtagcagcac	ccaccactgt	gaaggagatg	2460
gacagtaatg	agaaagcccc	tcaacacact	ctgccgccac	ctccgccacc	acccgacaac	2520
ctggatcatc	cccaacccat	ggagcaggga	accagtgatg	tttccggagc	catggaggaa	2580
gaagccaaac	tggagggaat	ctcaagccc	atggcagccc	tcaccaaga	aggggagggc	2640
accagcaccc	ctttggtgga	agagctgaac	ttaccggaag	ccatgaagaa	ggatccagga	2700
gagagcagcg	gcaggaaggc	ctgtgaagta	tgtggccaga	gcttttctac	ccagacagct	2760
ctggaggagc	atcagaagac	ccatcccaag	gatgggccac	tcttcaactg	tgtcttctgc	2820
aggcagggct	tccttgaccg	tgtaccctc	aagaagcaca	tgtgtttggc	tcaccaccag	2880
gtaccgcctt	ttgcacccca	tggccctcag	aatattgcta	ctctttcctt	ggtccctggc	2940
tgttctcctt	ccatcccttc	tcagggctc	tcccattcc	ctcgaaaaga	tgacccacc	3000
atgccatgag	cctgctttct	gtacctggtc	ctctatgacc	cagagagcag	aaacctgaga	3060
gcttcataga	ggaactccaa	gatttactca	ccctcctctt	gtcctttctc	aagtccctgac	3120
atgatgtttc	tagtggcttc	ttctctagtc	cctgagcttg	acaattgcct	tgaaagaga	3180
atgtccctt	aagaaat	tatcacctt	ttgttctgtg	taactaagg	aaacaaat	3240
cctatagctt	ttacattctc	aagggggagc	tctctcctct	tctccctt	cctttggcag	3300
gtatactaga	accccatcc	ttggagtggc	agccttggtc	caaggggctg	gcaactgtcc	3360
atggaaggcc	cagcgttact	ccttgggtgat	cttgaccacc	ctgcaagact	ttctagggcc	3420
gggaccttct	tgagaagctt	gtaaggggtg	gtaggtttct	ttctgcaacc	actaccagct	3480
tttccactga	gccttgaggt	tctggacct	cctgcattgc	cactcggg	ctagtaccat	3540

# COPY

```

cattgctgtg aaagcccagg aactgtgttt cacaagggtga ctccagtgac atgatccaga 3600
gaggcaaaga acatagcctc cggaagttag ggctgtgccc aacaagcaca ccggaagaaa 3660
gaagaaacta taacttcttt ctcttcccc cctgctccag agagtgtctg caataaagat 3720
attctagcaa ttggtgactc accctagaag gtagggacaa gtgaaggact gggacccttt 3780
ttgcagtatg ttccttgact cgccacattg aggcaaagat agtggctggt caagatgcc 3840
ggactactcc agcttcccat catgtcctct caaccaacaa gcaggtttcc taccaagagg 3900
tctctcgtgt gatagtttag ggagtatgaa gtttctaact ctaaagaatc ctggttgtga 3960
ggatgattat ttaagcaatg atggggagtt gagggttgtt gctaaaacag gcattgctgg 4020
gaatctatgt gatgaagaac aggacttgat gtaaggggac tcgatgttca gctcttgtga 4080
gtatgaacgt tttctttgag ctaatggtga tgtggtatgc agaggtacca ggggccatgg 4140
gggtgtgtgt gcttcctgtc actagaatgt ttttagtttt agatgactcc ctattttatt 4200
ccctcacccc ttgtatttcc cttgctgtct tctcaaaacc cctttcctcc cccagttttg 4260
cctgaccatg ggccagagct tatgtcttat tttttttcta gaagttgaga gacagagctt 4320
caagtggttt ccccccgtct ctgtcttgta gtgagatgta gtatttactc ttaacatagg 4380
atcctgtgga acaggtgttc tgagaagact gaattttgct gttagctgtt gtcaatgatg 4440
attctctaaa gtagtgggct ccagagctcc ctaacacagt gaaatgtgta agagccgaga 4500
ggggagatac tagaattttt tccttcatca ttaaagggtg tttggct 4547

```

<210> 5

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> derived from human Sal2 gene

<400> 5

ccacaaccat ggcgaatccg ag

22

<210> 6

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> derived from human Sal2 gene

<400> 6

ggtgatggaa ggcgaacagc cagg

24

<210> 7

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> derived from human Sal2 gene

<400> 7

cttgtaatt agagcctcgg tatacc

26

<210> 8

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> derived from human Sal2 gene



# COPY

<400> 8  
gcacggagga cccagaatct gg

22

<210> 9  
<211> 63  
<212> DNA  
<213> Polyoma virus

<400> 9  
gatatacttt gtaatgtgca agaaggcgac gacccttga aggacatatg tgaatatagc 60  
tga 63

<210> 10  
<211> 20  
<212> PRT  
<213> Polyoma virus

<400> 10  
Asp Ile Leu Cys Asn Val Gln Glu Gly Asp Asp Pro Leu Lys Asp Ile  
1 5 10 15  
Cys Glu Tyr Ser  
20

<210> 11  
<211> 19  
<212> PRT  
<213> TMD25 mutant Polyoma virus

<400> 11  
Asp Ile Leu Cys Asn Val Gln Glu Asp Phe Val Met Cys Lys Lys Ala  
1 5 10 15  
Thr Thr Pro

<210> 12  
<211> 60  
<212> DNA  
<213> TMD25 mutant Polyoma virus

<400> 12  
gatatacttt gtaatgtgca agaagacttt gtaatgtgca agaaggcgac gacccttga 60

<210> 13  
<211> 16  
<212> PRT  
<213> Polyoma virus

<400> 13  
Asn Val Gln Glu Gly Asp Asp Pro Leu Lys Asp Ile Cys Glu Tyr Ser  
1 5 10 15

<210> 14  
<211> 14  
<212> PRT  
<213> Artificial Sequence

# COPY

<220>

<223> derived from Polyoma virus large T antigen

<400> 14

Asn Val Gln Glu Gly Asp Asp Pro Leu Lys Asp Ile Cys Glu  
1 5 10

<210> 15

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> derived from Polyoma virus large T antigen

<400> 15

Asn Val Gln Glu Gly Asp Asp Pro Leu Lys  
1 5 10

<210> 16

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> derived from Polyoma virus large T antigen

<400> 16

Asn Val Gln Glu Gly Asp Asp  
1 5

<210> 17

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> derived from Polyoma virus large T antigen

<400> 17

Asn Val Gln Glu  
1

<210> 18

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> derived from Polyoma virus large T antigen

<400> 18

Asn Val Gln Glu Gly Asp Asp Leu Lys Asp Ile Cys Glu Tyr Ser  
1 5 10 15

# COPY

<210> 19  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> dervived from Polyoma virus large T antigen

<400> 19  
 Asn Val Gln Glu Gly Asp Asp Pro Lys Asp Ile Cys Glu Tyr Ser  
 1 5 10 15

<210> 20  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> dervived from Polyoma virus large T antigen

<400> 20  
 Asn Val Gln Glu Gly Asp Asp Pro Leu Asp Ile Cys Glu Tyr Ser  
 1 5 10 15

<210> 21  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> dervived from Polyoma virus large T antigen

<400> 21  
 Asn Val Gln Glu Gly Asp Asp Asp Ile Cys Glu Tyr Ser  
 1 5 10

<210> 22  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> derived from Polyoma virus large T antigen

<400> 22  
 cgtcacctga ggtgacacag caaagc

26

<210> 23  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> derived from Polyoma virus large T antigen

<400> 23

# COPY

cgcttccagg actgcaggct tcctg 25

<210> 24  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> derived from Polyoma virus large T antigen

<400> 24  
 cagaccccaa atctgcagat actcag 26

<210> 25  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> derived from Polyoma virus large T antigen

<400> 25  
 cactggaatt ggaactcttc tgtcgag 27

<210> 26  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> derived from Polyoma virus large T antigen

<400> 26  
 gaagtaggag tcaccgtcct gtttacc 27

<210> 27  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> derived from Polyoma virus large T antigen

<400> 27  
 gatgtctctg tatagccctg gctgtc 26

<210> 28  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> derived from Polyoma virus large T antigen

<400> 28  
 gctgaacggg aagctcactg gcatgg 26

<210> 29  
 <211> 26

# COPY

<212> DNA

<213> Artificial Sequence

<220>

<223> derived from Polyoma virus large T antigen

<400> 29

gaggtccacc accctgttgc tgtagc

26

<210> 30

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> derived from Polyoma virus large T antigen

<400> 30

aaggagaugg acaguaauga g

21

<210> 31

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> derived from Polyoma virus large T antigen

<400> 31

aaccccauua ccuccagaau c

21

<210> 32

<211> 3869

<212> DNA

<213> Mus musculus

<400> 32

```

gggggggtttg aaatggcttc tcggttaacc cgggccagac tcaggatatct gctatagaag 60
ggaaacaagt gaaagttttc ccccccttgc atcatggctc agtttggagg acagaagaat 120
ccaccatggg ctactcagtt tacagccact gcggtctcac aaccagctgc actaggtgtt 180
cagcagccat cacttctggg agcatctcct accatttata ccagcagac tgcattggcg 240
gcggcaggcc ttaccacaca aacgccagca aactatcagt taacacaaac tgcggcactg 300
cagcaacaag ctgcagctgt attacagcag caatattcac aacctcagca ggccttgtat 360
agtgtgcagc agcagttgca acaacctcag cagaccattt taacacagcc agctgttgca 420
ttgccacaa gccttagcct gtcgactcct cagcctgcag cacagattac tgtatcatat 480
ccaacaccaa ggtccagtca acagcaaact caacctcaga agcagcgtgt tttcacagga 540
gtggttacaa agctacatga tacatttgga tttgtggatg aagatgtatt ctttcagctt 600
ggtgctgtta aagggaaaac ccccaaagt ggtgatagag tattggttga agcaacttat 660
aatcctaata tgccttttaa atggaatgca caaagaattc aaacactacc aaatcagaat 720
cagctcaca cgcaaccttt actgaagact ccgactgctg ttattcagcc gattgtgcca 780
cagacaacgt ttggtgttca ggcacagccc caacccagc cattattgca ggcccagatc 840
tcagctgcct ctattacacc actattgcag acgcagccac agcccttatt acagcagcca 900
cagcagaaag ctgggtttatt gcagcctcct gtccgaatag tgtcacagcc acaacctgcg 960
cggagattag atccaccatc acgattttca ggaagaaacg acagagggga tcaagtacct 1020
aatagaaaag atgaccgaag tcgtgaaagg gacagagaaa gacgcagatc tagagaaaga 1080
tcacctcaga ggaaacgttc ccggagagg tcaccccgga gagaaagaga gcgctccctt 1140
cggagagtcc gtcgtgtcgt tccacggtac acagtgcagt tttcaaagtt ttcttttagat 1200
tgtcccagtt gtgacatgat ggaactaagg cgccgttatc agaacttata tattcctagt 1260
gacttttttg atgctcagtt tacatgggtg gatgctttcc ctttgtcaag accatttcaa 1320

```

COPY

```

ctgggaaatt actgcaattt ttatgtgatg caccgagaag tagagtcctt agaaaaaaat 1380
atggctgttc ttgatccacc tgatgctgac cacctgtaca gtgcaaagg aatgctgatg 1440
gctagcccta gtatggaaga cttgtatcat aagtcatgtg ctcttgctga agaccacaa 1500
gaccttcgtg atggttttca gcatcctgct agacttgta agtttctagt gggaatgaaa 1560
ggcaaggatg aagccatggc cattggaggc cactgggtctc cttcgctgga tggaccaaac 1620
ccagaaaaag atccctctgt gttgattaaa actgccattc gttgttgtaa ggctctgaca 1680
ggcattgatc taagtgtatg cacacagtgg taccgttttg cagagattcg ctaccatcgc 1740
cctgaggaga ccacaaaggg gcgtacagtt ccagctcatg tggagacagt gggttttattt 1800
ttcccggtatg tttggcattg ccttcccacc cgctcagagt gggaaaccct ctcccgagga 1860
tacaagcagc agctggtcga gaagcttcag ggtgaacgca agaaggctga tggagaacag 1920
gatgaagaag agaaggatga tggatgaagt aaagagatcg ccactcctac ccattggtct 1980
aagcttgatc caaaggcaat gaaggtaaat gatctccgaa aagaattaga aagtcgagct 2040
ctcagttcca aaggactaaa atcgcagtta atagctcgcc taacaaagca gcttaaaata 2100
gaagaacaaa aagaagagca gaaggaatta gagaagtctg aaaaggaaga ggaagatgag 2160
gatgataaga agtctgagga tgataaagag gaagaagaaa gaaaacgtca agaagaagt 2220
gaacgacagc gtcaagaaag aagatacatt ttgcctgatg aacctgccat aattgtgcat 2280
ccgaactggg ctgcaaaaag tggcaagttt gattgcagca tcatgtcttt gagtgtcctt 2340
ttggattaca gattggaaga taataaagaa cattcttttg aggtttcact gtttgcagaa 2400
cttttcaatg aaatgcttca aagagacttt ggggttagaa tatacaaata attactctct 2460
cttcctgaga aagaggacaa aaaagataag gagaagaaaa gcaaaaaaga agagagaaaa 2520
gataaaaaag aagaagagca agatgatatt gatgaaccaa aaccaaaccg gagaaaaata 2580
ggcgacgata aagacaaaaa agaagacaga gatgagagaa agaaagaaga aaaaagaaaa 2640
gatgattcta aagatgatga tgaaactgaa gaagataaca atcaagatga gtatgacca 2700
atggaggcag aggaagctga ggatgaagat gacgataggg aggaggagga agtaaaacga 2760
gatgacaaaa gggatgtcag ccggtactgc aaggacagac ctgcgaaaga taaggaaaaa 2820
gagaagcctc aaatggtcac agttaacagg gatctgctaa tggcctttgt ttattttgat 2880
caaagtcatt cgggttacct tcttgaaaag gatttggaag aaatactata tactcttgga 2940
ctgcatcttt caccgggtca ggtaaagaaa cttcttaata aagtagtact ccgagaatcg 3000
tgcttttatc ggaaattaac agacacctcg aaagatgatg agaaccatga agagtcagag 3060
gcactgcagg aagacatgct aggaacacaga ttattacttc caacaccaac aataaaacag 3120
gaatcaaaaag atggagagga aaatgtaggg cttattgtgt acaatggtgc aatggtggat 3180
gttgggagtc tcctacaaaa actggaaaag agtgagaaaag taagagctga ggtggaacag 3240
aagctccagt tactagagga gaaaacagat gaagatggga aaactatatt aaacttgag 3300
aactctaaca aaagcctctc tggatgaact agagaggtca aaaaagacct tggatcaatta 3360
caagaaaacc tggaggtttc agaaaacatg aatttgcaat ttgaaaacca attgaataaa 3420
acactcagaa acttatctac agttatggat gatatccaca ctgtcctcaa aaaggataat 3480
gtaaagagtg aagacagaga tgagaaatcc aaggagaacg gctcaggtgt atgacacagt 3540
gcacttgggg atgagtgtgt taatagtgtg ctataaaca aataatcatg agatgggaat 3600
gtttcacggc agtgcattgt tgactttagt agtataaaca tatatgttag ttcaaattg 3660
gtataaagtt ttatgaatgt gagtctgctt ttgaaaattg cctgtaattt ctagcattca 3720
aattattaaa tactcactga gtgaagaatt ttgcattgca aaacctttta ggatgaactt 3780
ggttatagtt tccccataaa agttcatcag tgcattgac aatgacaagt aattaaaacc 3840
aaaaaaaaa aaacaaaaca ccaaccagg
3869

```

<210> 33

<211> 1153

<212> PRT

<213> Mus musculus

<400> 33

```

Lys Phe Ser Pro Pro Cys Ile Met Ala Gln Phe Gly Gly Gln Lys Asn
 1           5           10           15
Pro Pro Trp Ala Thr Gln Phe Thr Ala Thr Ala Val Ser Gln Pro Ala
          20          25          30
Ala Leu Gly Val Gln Gln Pro Ser Leu Leu Gly Ala Ser Pro Thr Ile
          35          40          45
Tyr Thr Gln Gln Thr Ala Leu Ala Ala Ala Gly Leu Thr Thr Gln Thr
          50          55          60
Pro Ala Asn Tyr Gln Leu Thr Gln Thr Ala Ala Leu Gln Gln Gln Ala

```



65					70					75					80
Ala	Ala	Val	Leu	Gln	Gln	Gln	Tyr	Ser	Gln	Pro	Gln	Gln	Ala	Leu	Tyr
				85					90					95	
Ser	Val	Gln	Gln	Gln	Leu	Gln	Gln	Pro	Gln	Gln	Thr	Ile	Leu	Thr	Gln
				100				105					110		
Pro	Ala	Val	Ala	Leu	Pro	Thr	Ser	Leu	Ser	Leu	Ser	Thr	Pro	Gln	Pro
				115			120					125			
Ala	Ala	Gln	Ile	Thr	Val	Ser	Tyr	Pro	Thr	Pro	Arg	Ser	Ser	Gln	Gln
				130			135				140				
Gln	Thr	Gln	Pro	Gln	Lys	Gln	Arg	Val	Phe	Thr	Gly	Val	Val	Thr	Lys
145					150					155					160
Leu	His	Asp	Thr	Phe	Gly	Phe	Val	Asp	Glu	Asp	Val	Phe	Phe	Gln	Leu
				165					170					175	
Gly	Ala	Val	Lys	Gly	Lys	Thr	Pro	Gln	Val	Gly	Asp	Arg	Val	Leu	Val
				180				185					190		
Glu	Ala	Thr	Tyr	Asn	Pro	Asn	Met	Pro	Phe	Lys	Trp	Asn	Ala	Gln	Arg
				195			200					205			
Ile	Gln	Thr	Leu	Pro	Asn	Gln	Asn	Gln	Ser	Gln	Thr	Gln	Pro	Leu	Leu
				210			215					220			
Lys	Thr	Pro	Thr	Ala	Val	Ile	Gln	Pro	Ile	Val	Pro	Gln	Thr	Thr	Phe
225					230					235					240
Gly	Val	Gln	Ala	Gln	Pro	Gln	Pro	Gln	Ser	Leu	Leu	Gln	Ala	Gln	Ile
				245					250					255	
Ser	Ala	Ala	Ser	Ile	Thr	Pro	Leu	Leu	Gln	Thr	Gln	Pro	Gln	Pro	Leu
				260				265					270		
Leu	Gln	Gln	Pro	Gln	Gln	Lys	Ala	Gly	Leu	Leu	Gln	Pro	Pro	Val	Arg
				275			280					285			
Ile	Val	Ser	Gln	Pro	Gln	Pro	Ala	Arg	Arg	Leu	Asp	Pro	Pro	Ser	Arg
				290			295				300				
Phe	Ser	Gly	Arg	Asn	Asp	Arg	Gly	Asp	Gln	Val	Pro	Asn	Arg	Lys	Asp
305					310					315					320
Asp	Arg	Ser	Arg	Glu	Arg	Asp	Arg	Glu	Arg	Arg	Arg	Ser	Arg	Glu	Arg
				325					330					335	
Ser	Pro	Gln	Arg	Lys	Arg	Ser	Arg	Glu	Arg	Ser	Pro	Arg	Arg	Glu	Arg
				340				345					350		
Glu	Arg	Ser	Pro	Arg	Arg	Val	Arg	Arg	Val	Val	Pro	Arg	Tyr	Thr	Val
				355			360					365			
Gln	Phe	Ser	Lys	Phe	Ser	Leu	Asp	Cys	Pro	Ser	Cys	Asp	Met	Met	Glu
				370			375				380				
Leu	Arg	Arg	Arg	Tyr	Gln	Asn	Leu	Tyr	Ile	Pro	Ser	Asp	Phe	Phe	Asp
385					390					395					400
Ala	Gln	Phe	Thr	Trp	Val	Asp	Ala	Phe	Pro	Leu	Ser	Arg	Pro	Phe	Gln
				405					410					415	
Leu	Gly	Asn	Tyr	Cys	Asn	Phe	Tyr	Val	Met	His	Arg	Glu	Val	Glu	Ser
				420				425					430		
Leu	Glu	Lys	Asn	Met	Ala	Val	Leu	Asp	Pro	Pro	Asp	Ala	Asp	His	Leu
				435			440					445			
Tyr	Ser	Ala	Lys	Val	Met	Leu	Met	Ala	Ser	Pro	Ser	Met	Glu	Asp	Leu
					455						460				
Tyr	His	Lys	Ser	Cys	Ala	Leu	Ala	Glu	Asp	Pro	Gln	Asp	Leu	Arg	Asp
465					470					475					480
Gly	Phe	Gln	His	Pro	Ala	Arg	Leu	Val	Lys	Phe	Leu	Val	Gly	Met	Lys
				485					490					495	
Gly	Lys	Asp	Glu	Ala	Met	Ala	Ile	Gly	Gly	His	Trp	Ser	Pro	Ser	Leu
				500				505					510		
Asp	Gly	Pro	Asn	Pro	Glu	Lys	Asp	Pro	Ser	Val	Leu	Ile	Lys	Thr	Ala
				515			520					525			
Ile	Arg	Cys	Cys	Lys	Ala	Leu	Thr	Gly	Ile	Asp	Leu	Ser	Val	Cys	Thr
				530			535				540				

COPY

Gln	Trp	Tyr	Arg	Phe	Ala	Glu	Ile	Arg	Tyr	His	Arg	Pro	Glu	Glu	Thr	545	550	555	560
His	Lys	Gly	Arg	Thr	Val	Pro	Ala	His	Val	Glu	Thr	Val	Val	Leu	Phe	565	570		575
Phe	Pro	Asp	Val	Trp	His	Cys	Leu	Pro	Thr	Arg	Ser	Glu	Trp	Glu	Thr	580	585		590
Leu	Ser	Arg	Gly	Tyr	Lys	Gln	Gln	Leu	Val	Glu	Lys	Leu	Gln	Gly	Glu	595	600	605	
Arg	Lys	Lys	Ala	Asp	Gly	Glu	Gln	Asp	Glu	Glu	Glu	Lys	Asp	Asp	Gly	610	615	620	
Glu	Val	Lys	Glu	Ile	Ala	Thr	Pro	Thr	His	Trp	Ser	Lys	Leu	Asp	Pro	625	630	635	640
Lys	Ala	Met	Lys	Val	Asn	Asp	Leu	Arg	Lys	Glu	Leu	Glu	Ser	Arg	Ala	645	650		655
Leu	Ser	Ser	Lys	Gly	Leu	Lys	Ser	Gln	Leu	Ile	Ala	Arg	Leu	Thr	Lys	660	665		670
Gln	Leu	Lys	Ile	Glu	Glu	Gln	Lys	Glu	Glu	Gln	Lys	Glu	Leu	Glu	Lys	675	680	685	
Ser	Glu	Lys	Glu	Glu	Glu	Asp	Glu	Asp	Asp	Lys	Lys	Ser	Glu	Asp	Asp	690	695	700	
Lys	Glu	Glu	Glu	Glu	Arg	Lys	Arg	Gln	Glu	Glu	Val	Glu	Arg	Gln	Arg	705	710	715	720
Gln	Glu	Arg	Arg	Tyr	Ile	Leu	Pro	Asp	Glu	Pro	Ala	Ile	Ile	Val	His	725	730		735
Pro	Asn	Trp	Ala	Ala	Lys	Ser	Gly	Lys	Phe	Asp	Cys	Ser	Ile	Met	Ser	740	745		750
Leu	Ser	Val	Leu	Leu	Asp	Tyr	Arg	Leu	Glu	Asp	Asn	Lys	Glu	His	Ser	755	760	765	
Phe	Glu	Val	Ser	Leu	Phe	Ala	Glu	Leu	Phe	Asn	Glu	Met	Leu	Gln	Arg	770	775	780	
Asp	Phe	Gly	Val	Arg	Ile	Tyr	Lys	Ser	Leu	Leu	Ser	Leu	Pro	Glu	Lys	785	790	795	800
Glu	Asp	Lys	Lys	Asp	Lys	Glu	Lys	Lys	Ser	Lys	Lys	Glu	Glu	Arg	Lys	805	810		815
Asp	Lys	Lys	Glu	Glu	Arg	Glu	Asp	Asp	Ile	Asp	Glu	Pro	Lys	Pro	Lys	820	825		830
Arg	Arg	Lys	Ser	Gly	Asp	Asp	Lys	Asp	Lys	Lys	Glu	Asp	Arg	Asp	Glu	835	840	845	
Arg	Lys	Lys	Glu	Glu	Lys	Arg	Lys	Asp	Asp	Ser	Lys	Asp	Asp	Asp	Glu	850	855	860	
Thr	Glu	Glu	Asp	Asn	Asn	Gln	Asp	Glu	Tyr	Asp	Pro	Met	Glu	Ala	Glu	865	870	875	880
Glu	Ala	Glu	Asp	Glu	Asp	Asp	Asp	Arg	Glu	Glu	Glu	Glu	Val	Lys	Arg	885	890		895
Asp	Asp	Lys	Arg	Asp	Val	Ser	Arg	Tyr	Cys	Lys	Asp	Arg	Pro	Ala	Lys	900	905		910
Asp	Lys	Glu	Lys	Glu	Lys	Pro	Gln	Met	Val	Thr	Val	Asn	Arg	Asp	Leu	915	920	925	
Leu	Met	Ala	Phe	Val	Tyr	Phe	Asp	Gln	Ser	His	Cys	Gly	Tyr	Leu	Leu	930	935	940	
Glu	Lys	Asp	Leu	Glu	Glu	Ile	Leu	Tyr	Thr	Leu	Gly	Leu	His	Leu	Ser	945	950	955	960
Arg	Ala	Gln	Val	Lys	Lys	Leu	Leu	Asn	Lys	Val	Val	Leu	Arg	Glu	Ser	965	970		975
Cys	Phe	Tyr	Arg	Lys	Leu	Thr	Asp	Thr	Ser	Lys	Asp	Asp	Glu	Asn	His	980	985		990
Glu	Glu	Ser	Glu	Ala	Leu	Gln	Glu	Asp	Met	Leu	Gly	Asn	Arg	Leu	Leu	995	1000	1005	
Leu	Pro	Thr	Pro	Thr	Ile	Lys	Gln	Glu	Ser	Lys	Asp	Gly	Glu	Glu	Asn				



# COPY

1010	1015	1020
Val Gly Leu Ile Val Tyr Asn Gly Ala Met Val Asp Val Gly Ser Leu		
1025	1030	1035
Leu Gln Lys Leu Glu Lys Ser Glu Lys Val Arg Ala Glu Val Glu Gln		1040
	1045	1050
Lys Leu Gln Leu Leu Glu Glu Lys Thr Asp Glu Asp Gly Lys Thr Ile		1055
	1060	1065
Leu Asn Leu Glu Asn Ser Asn Lys Ser Leu Ser Gly Glu Leu Arg Glu		1070
	1075	1080
Val Lys Lys Asp Leu Gly Gln Leu Gln Glu Asn Leu Glu Val Ser Glu		1085
	1090	1095
Asn Met Asn Leu Gln Phe Glu Asn Gln Leu Asn Lys Thr Leu Arg Asn		1100
1105	1110	1115
Leu Ser Thr Val Met Asp Asp Ile His Thr Val Leu Lys Lys Asp Asn		1120
	1125	1130
Val Lys Ser Glu Asp Arg Asp Glu Lys Ser Lys Glu Asn Gly Ser Gly		1135
	1140	1145
Val		1150

<210> 34  
 <211> 3856  
 <212> DNA  
 <213> Homo sapiens

<400> 34

gaagttggcg	catgcgccta	aagctgacgg	gtttgaaatg	gcttcgatgt	tagccgggac	60
ccgactcaga	tcgatgctat	agaagacaaa	caaggaaagg	ttttttttcc	ttttgcatca	120
tggctcaatt	tggaggacag	aagaatccgc	catgggctac	tcagttttaca	gccactgcag	180
tatcacagcc	agctgcactg	ggtgttcaac	agccatcact	ccttggagca	tctcctacca	240
tttatacaca	gcaaactgca	ttggcagcag	caggccttac	cacacaaact	ccagcaaaact	300
atcagtttaac	acaaactgct	gcattgcagc	aacaagccgc	agctgcagca	gctgcattac	360
aacagcaata	ttcacaacct	cagcaggccc	tgtatagtgt	gcaacaacag	ttacagcaac	420
cccagcaaac	cctcttaaca	cagccagctg	ttgcactgcc	tacaagcctt	agcctgtcta	480
ctcctcagcc	aacagcacaa	ataactgtat	catatccaac	accaagggtcc	agtcaacagc	540
aaacccagcc	tcagaagcag	cgtgttttca	caggggtggt	tacaaaacta	catgatacat	600
ttggatttgt	ggatgaagat	gtattctttc	agcttagtgc	tgtcaaaggg	aaaacccccc	660
aagtagggtga	cagagtattg	gttgaagcta	cttataatcc	taatatgcct	tttaaatgga	720
atgcacagag	aattcaaaca	ctaccaaata	agaatcagtc	gcaaaccag	ccattactga	780
agactcctcc	tgtgttactt	cagccaattg	caccacagac	aacatttggt	gttcagactc	840
agccccagcc	ccagtcactg	ctgcaggcac	agatttcagc	agcttctatt	acaccactat	900
tgcagactca	accacagccc	ttattacagc	agcctcagca	aaaagctggt	ttattgcagc	960
ctcctgttcg	tatagtttca	cagccacaac	cggcacgacg	attagatccc	ccatcccgat	1020
tttcaggaag	aaatgacaga	gggatcaag	tgcctaacag	aaaagatgat	cgaagtgcgtg	1080
agagagagag	agaaagacgt	agatcgagag	aaagatcacc	tcagaggaaa	cgttcccggg	1140
aaagatctcc	acgaagagag	cgagagcgat	cacctcggag	agttcgacgt	gttggtccac	1200
gttacacagt	tcagttttca	aagttttctt	tagattgtcc	cagttgtgac	atgatggaac	1260
taaggcgccg	ttatcaaaat	ttgtatatac	ctagtgactt	ttttgatgct	caattttacat	1320
gggtgatgc	tttccctttg	tcaagacctt	ttcagctggg	aaattactgc	aatttttatg	1380
taatgcacag	agaagtagag	tccttagaaa	aaaatatggc	cattcttgat	ccaccagatg	1440
ctgaccactt	atacagtgca	aaggtaatgc	tgatggctag	ccctagtatg	gaagattttat	1500
atcataagtc	atgtgctctt	gctgaggacc	cacaagaact	tcgagatgga	ttccaacatc	1560
ctgctagact	tgtaagtgtt	ttagtgggca	tgaaaggcaa	ggatgaagct	atggccattg	1620
gaggccactg	gtctccttcg	ttggatggac	cagacccaga	aaaagatccc	tctgtgttga	1680
ttaagactgc	tattcgttgt	tgtaaggctc	tgacaggcat	tgatctaagt	gtgtgcacac	1740
aatgggtaccg	ttttgcagag	attcgctacc	atcgccctga	ggagaccac	aaggggcgta	1800
cagttccagc	tcagtgtggag	acagtgggtt	tatttttccc	ggatgtttgg	cattgccttc	1860
ccacccgctc	agagtgggaa	accctctccc	gaggatacaa	gcagcagctg	gtcgagaagc	1920

# COPY

```

ttcaggggtga acgcaaggag gctgatggag aacaggatga agaagagaag gatgatgggtg 1980
aagctaaaga aatttctaca cctacccatt ggtctaaact tgatccaaag acaatgaagg 2040
taaatgacct ccgaaaagaa ttagaaggct gagctcttag ttccaaagga ttaaaatccc 2100
agttaatagc ccgattgaca aaacagctta aagtagagga acaaaaagaa gaacagaagg 2160
agttagagaa atctgaaaaa gaagaggatg aggatgatga taggaaatct gaagacgata 2220
aagaggaaga agaaaggaaa cgtcaagagg aaatagaacg ccagcgctcg gaaagaagat 2280
atattttgcc tgatgaaccg gccatcattg tacatccaaa ttgggctgca aaaagtggca 2340
agtttgattg tagcatcatg tctttgagtg tcctattgga ctacagatta gaggataata 2400
aagaacattc atttgaggtt tcattgtttg cggaactttt caacgaaatg cttcaaagag 2460
attttggtgt ccgtatatac aaatcattac tgtctcttcc tgagaaagag gacaaaaaag 2520
aaaaggataa aaaaagcaaa aaagatgaga gaaaagataa aaaagaagaa agagatgatg 2580
aaactgatga accaaaaccc aaacggagaa aatcaggcga tgataaagat aaaaaagaag 2640
atagagatga aaggaagaaa gaagataaaa gaaaagggtga ttctaaagat gatgatgaaa 2700
ctgaagaaga taacaatcaa gatgaatatg acctatgga agcagaagaa gctgaggatg 2760
aagaagatga tagggatgag gaagaaatga ccaaacgaga tgacaaaaga gatatcaaca 2820
gatactgcaa ggagaggccc tctaaagata aggaaaaaga aaagactcaa atgatcacia 2880
ttaacagaga tctgttaatg gcttttggtt attttgatca aagtcattgt ggttaccttc 2940
ttgaaaagga tttggaagaa atactttata ctcttgact acatctttct cgggctcagg 3000
taaagaagct tcttaataaa gtagtgctcc gtgaatcttg cttttaccgg aaattaacag 3060
acacctcaaa agatgaagag aacctgaag agtctgagtc attgcaggaa gatatgctag 3120
gaaacagatt attacttcca acaccaacag taaagcagga atcaaaggat gtggaagaaa 3180
atgttgacct cattgtgtac aatggtgcaa tggtagatgt aggaagcctc ttgcaaaaat 3240
tggaagagag cgaaaaagta agagctgagg tagaacagaa gctgcagtta ctagaagaaa 3300
aaacagatga agatgaaaaa accatattaa atttggagaa ttccaacaaa agcctctctg 3360
gtgaactcag agaagttaaa aaggacctta gtcagttaca agaaaactta aagatttcag 3420
aaaacatgag tttaacaattt gaaaaccaa tgaataagac aatcagaac ttatctacgg 3480
taatggatga aatccacact gttctcaaga aggataatgt aaagaatgaa gacaaagatc 3540
aaaaatccaa ggagaatggt gccagtgtat gataaaatcc atgtagtgat gaggaatggt 3600
gttaataaat gtaatatata aaaatcatga tataagaatg tttgaagggt atgcatgttt 3660
gatttttagta gtataaatgt atttttagttc aaatgatgta taaagtttta tgaatgtgag 3720
tttctgcttt tgaaaattgc ttgtaattcc tagccttcaa attattaaac actccttgag 3780
tgaaataatt ttgcattgca aagtgtttta ggatgaactt tgttatagtt ttaactccaa 3840
taaagttcat cagttt 3856

```

<210> 35

<211> 1172

<212> PRT

<213> Homo sapiens

<400> 35

```

Pro Gly Pro Asp Ser Asp Arg Cys Tyr Arg Arg Gln Thr Arg Lys Gly
1          5          10          15
Phe Phe Ser Phe Cys Ile Met Ala Gln Phe Gly Gly Gln Lys Asn Pro
20          25          30
Pro Trp Ala Thr Gln Phe Thr Ala Thr Ala Val Ser Gln Pro Ala Ala
35          40          45
Leu Gly Val Gln Gln Pro Ser Leu Leu Gly Ala Ser Pro Thr Ile Tyr
50          55          60
Thr Gln Gln Thr Ala Leu Ala Ala Gly Leu Thr Thr Gln Thr Pro
65          70          75          80
Ala Asn Tyr Gln Leu Thr Gln Thr Ala Ala Leu Gln Gln Gln Ala Ala
85          90          95
Ala Ala Ala Ala Ala Leu Gln Gln Gln Tyr Ser Gln Pro Gln Gln Ala
100          105          110
Leu Tyr Ser Val Gln Gln Gln Leu Gln Gln Pro Gln Gln Thr Leu Leu
115          120          125
Thr Gln Pro Ala Val Ala Leu Pro Thr Ser Leu Ser Leu Ser Thr Pro
130          135          140
Gln Pro Thr Ala Gln Ile Thr Val Ser Tyr Pro Thr Pro Arg Ser Ser

```

# COPY

145	150	155	160
Gln Gln Gln Thr	Gln Pro Gln Lys Gln Arg Val Phe Thr Gly Val Val		
	165	170	175
Thr Lys Leu His Asp Thr Phe Gly Phe Val Asp Glu Asp Val Phe Phe			
	180	185	190
Gln Leu Ser Ala Val Lys Gly Lys Thr Pro Gln Val Gly Asp Arg Val			
	195	200	205
Leu Val Glu Ala Thr Tyr Asn Pro Asn Met Pro Phe Lys Trp Asn Ala			
	210	215	220
Gln Arg Ile Gln Thr Leu Pro Asn Gln Asn Gln Ser Gln Thr Gln Pro			
225	230	235	240
Leu Leu Lys Thr Pro Ala Val Leu Gln Pro Ile Ala Pro Gln Thr			
	245	250	255
Thr Phe Gly Val Gln Thr Gln Pro Gln Pro Gln Ser Leu Leu Gln Ala			
	260	265	270
Gln Ile Ser Ala Ala Ser Ile Thr Pro Leu Leu Gln Thr Gln Pro Gln			
	275	280	285
Pro Leu Leu Gln Gln Pro Gln Gln Lys Ala Gly Leu Leu Gln Pro Pro			
	290	295	300
Val Arg Ile Val Ser Gln Pro Gln Pro Ala Arg Arg Leu Asp Pro Pro			
305	310	315	320
Ser Arg Phe Ser Gly Arg Asn Asp Arg Gly Asp Gln Val Pro Asn Arg			
	325	330	335
Lys Asp Asp Arg Ser Arg Glu Arg Glu Arg Glu Arg Arg Ser Arg			
	340	345	350
Glu Arg Ser Pro Gln Arg Lys Arg Ser Arg Glu Arg Ser Pro Arg Arg			
	355	360	365
Glu Arg Glu Arg Ser Pro Arg Arg Val Arg Arg Val Val Pro Arg Tyr			
	370	375	380
Thr Val Gln Phe Ser Lys Phe Ser Leu Asp Cys Pro Ser Cys Asp Met			
385	390	395	400
Met Glu Leu Arg Arg Tyr Gln Asn Leu Tyr Ile Pro Ser Asp Phe			
	405	410	415
Phe Asp Ala Gln Phe Thr Trp Val Asp Ala Phe Pro Leu Ser Arg Pro			
	420	425	430
Phe Gln Leu Gly Asn Tyr Cys Asn Phe Tyr Val Met His Arg Glu Val			
	435	440	445
Glu Ser Leu Glu Lys Asn Met Ala Ile Leu Asp Pro Pro Asp Ala Asp			
	450	455	460
His Leu Tyr Ser Ala Lys Val Met Leu Met Ala Ser Pro Ser Met Glu			
465	470	475	480
Asp Leu Tyr His Lys Ser Cys Ala Leu Ala Glu Asp Pro Gln Glu Leu			
	485	490	495
Arg Asp Gly Phe Gln His Pro Ala Arg Leu Val Lys Phe Leu Val Gly			
	500	505	510
Met Lys Gly Lys Asp Glu Ala Met Ala Ile Gly Gly His Trp Ser Pro			
	515	520	525
Ser Leu Asp Gly Pro Asp Pro Glu Lys Asp Pro Ser Val Leu Ile Lys			
	530	535	540
Thr Ala Ile Arg Cys Cys Lys Ala Leu Thr Gly Ile Asp Leu Ser Val			
545	550	555	560
Cys Thr Gln Trp Tyr Arg Phe Ala Glu Ile Arg Tyr His Arg Pro Glu			
	565	570	575
Glu Thr His Lys Gly Arg Thr Val Pro Ala His Val Glu Thr Val Val			
	580	585	590
Leu Phe Phe Pro Asp Val Trp His Cys Leu Pro Thr Arg Ser Glu Trp			
	595	600	605
Glu Thr Leu Ser Arg Gly Tyr Lys Gln Gln Leu Val Glu Lys Leu Gln			
	610	615	620

# COPY

Gly	Glu	Arg	Lys	Glu	Ala	Asp	Gly	Glu	Gln	Asp	Glu	Glu	Glu	Lys	Asp
625					630					635					640
Asp	Gly	Glu	Ala	Lys	Glu	Ile	Ser	Thr	Pro	Thr	His	Trp	Ser	Lys	Leu
				645					650					655	
Asp	Pro	Lys	Thr	Met	Lys	Val	Asn	Asp	Leu	Arg	Lys	Glu	Leu	Glu	Gly
			660					665					670		
Arg	Ala	Leu	Ser	Ser	Lys	Gly	Leu	Lys	Ser	Gln	Leu	Ile	Ala	Arg	Leu
		675					680					685			
Thr	Lys	Gln	Leu	Lys	Val	Glu	Glu	Gln	Lys	Glu	Glu	Gln	Lys	Glu	Leu
	690					695					700				
Glu	Lys	Ser	Glu	Lys	Glu	Glu	Asp	Glu	Asp	Asp	Asp	Arg	Lys	Ser	Glu
705					710					715					720
Asp	Asp	Lys	Glu	Glu	Glu	Glu	Arg	Lys	Arg	Gln	Glu	Glu	Ile	Glu	Arg
			725						730					735	
Gln	Arg	Arg	Glu	Arg	Arg	Tyr	Ile	Leu	Pro	Asp	Glu	Pro	Ala	Ile	Ile
			740					745					750		
Val	His	Pro	Asn	Trp	Ala	Ala	Lys	Ser	Gly	Lys	Phe	Asp	Cys	Ser	Ile
		755					760					765			
Met	Ser	Leu	Ser	Val	Leu	Leu	Asp	Tyr	Arg	Leu	Glu	Asp	Asn	Lys	Glu
	770					775					780				
His	Ser	Phe	Glu	Val	Ser	Leu	Phe	Ala	Glu	Leu	Phe	Asn	Glu	Met	Leu
785					790					795					800
Gln	Arg	Asp	Phe	Gly	Val	Arg	Ile	Tyr	Lys	Ser	Leu	Leu	Ser	Leu	Pro
			805						810					815	
Glu	Lys	Glu	Asp	Lys	Lys	Glu	Lys	Asp	Lys	Lys	Ser	Lys	Lys	Asp	Glu
			820					825					830		
Arg	Lys	Asp	Lys	Lys	Glu	Glu	Arg	Asp	Asp	Glu	Thr	Asp	Glu	Pro	Lys
		835					840					845			
Pro	Lys	Arg	Arg	Lys	Ser	Gly	Asp	Asp	Lys	Asp	Lys	Lys	Glu	Asp	Arg
	850					855				860					
Asp	Glu	Arg	Lys	Lys	Glu	Asp	Lys	Arg	Lys	Gly	Asp	Ser	Lys	Asp	Asp
865					870					875					880
Asp	Glu	Thr	Glu	Glu	Asp	Asn	Asn	Gln	Asp	Glu	Tyr	Asp	Pro	Met	Glu
			885						890					895	
Ala	Glu	Glu	Ala	Glu	Asp	Glu	Glu	Asp	Asp	Arg	Asp	Glu	Glu	Glu	Met
			900					905					910		
Thr	Lys	Arg	Asp	Asp	Lys	Arg	Asp	Ile	Asn	Arg	Tyr	Cys	Lys	Glu	Arg
		915					920					925			
Pro	Ser	Lys	Asp	Lys	Glu	Lys	Glu	Lys	Thr	Gln	Met	Ile	Thr	Ile	Asn
	930					935					940				
Arg	Asp	Leu	Leu	Met	Ala	Phe	Val	Tyr	Phe	Asp	Gln	Ser	His	Cys	Gly
945					950					955					960
Tyr	Leu	Leu	Glu	Lys	Asp	Leu	Glu	Glu	Ile	Leu	Tyr	Thr	Leu	Gly	Leu
			965						970					975	
His	Leu	Ser	Arg	Ala	Gln	Val	Lys	Lys	Leu	Leu	Asn	Lys	Val	Val	Leu
			980				985						990		
Arg	Glu	Ser	Cys	Phe	Tyr	Arg	Lys	Leu	Thr	Asp	Thr	Ser	Lys	Asp	Glu
		995					1000					1005			
Glu	Asn	His	Glu	Glu	Ser	Glu	Ser	Leu	Gln	Glu	Asp	Met	Leu	Gly	Asn
	1010					1015					1020				
Arg	Leu	Leu	Leu	Pro	Thr	Pro	Thr	Val	Lys	Gln	Glu	Ser	Lys	Asp	Val
1025					1030					1035					1040
Glu	Glu	Asn	Val	Gly	Leu	Ile	Val	Tyr	Asn	Gly	Ala	Met	Val	Asp	Val
			1045						1050					1055	
Gly	Ser	Leu	Leu	Gln	Lys	Leu	Glu	Lys	Ser	Glu	Lys	Val	Arg	Ala	Glu
		1060					1065						1070		
Val	Glu	Gln	Lys	Leu	Gln	Leu	Leu	Glu	Glu	Lys	Thr	Asp	Glu	Asp	Glu
	1075					1080						1085			
Lys	Thr	Ile	Leu	Asn	Leu	Glu	Asn	Ser	Asn	Lys	Ser	Leu	Ser	Gly	Glu

COPY

1090					1095					1100					
Leu	Arg	Glu	Val	Lys	Lys	Asp	Leu	Ser	Gln	Leu	Gln	Glu	Asn	Leu	Lys
1105					1110					1115					1120
Ile	Ser	Glu	Asn	Met	Ser	Leu	Gln	Phe	Glu	Asn	Gln	Met	Asn	Lys	Thr
1125					1130					1135					
Ile	Arg	Asn	Leu	Ser	Thr	Val	Met	Asp	Glu	Ile	His	Thr	Val	Leu	Lys
1140					1145					1150					
Lys	Asp	Asn	Val	Lys	Asn	Glu	Asp	Lys	Asp	Gln	Lys	Ser	Lys	Glu	Asn
1155					1160					1165					
Gly	Ala	Ser	Val												
1170															

```
<210> 36
<211> 18
<212> PRT
<213> Mus musculus
```

```
<400> 36
Gly Gly Phe Glu Met Ala Ser Arg Leu Thr Arg Ala Arg Leu Arg Tyr
 1             5             10             15
Leu Leu
```

```
<210> 37
<211> 4
<212> PRT
<213> Mus musculus
```

<400> 37  
Lys Gly Asn Lys  
1

```
<210> 38
<211> 12
<212> PRT
<213> Mus musculus
```

```
<400> 38
His Ser Ala Leu Gly Asp Glu Cys Val Asn Ser Val
  1                   5                   10
```

```
<210> 39
<211> 24
<212> PRT
<213> Mus musculus
```

```

<400> 39
Asp Gly Asn Val Ser Arg Gln Cys Met Leu Asp Phe Ser Ser Ile Asn
 1          5          10          15
Ile Tyr Val Ser Ser Asn Asp Val
      20

```

$\langle 210 \rangle$	40
$\langle 211 \rangle$	15

# COPY

<212> PRT

<213> Mus musculus

<400> 40

Ser Phe Met Asn Val Ser Leu Leu Leu Lys Ile Ala Cys Asn Phe  
1 5 10 15

<210> 41

<211> 4

<212> PRT

<213> Mus musculus

<400> 41

His Ser Asn Tyr  
1

<210> 42

<211> 4

<212> PRT

<213> Mus musculus

<400> 42

Ile Leu Thr Glu  
1

<210> 43

<211> 8

<212> PRT

<213> Mus musculus

<400> 43

Arg Ile Leu His Cys Lys Thr Phe  
1 5

<210> 44

<211> 15

<212> PRT

<213> Mus musculus

<400> 44

Asp Glu Leu Gly Tyr Ser Phe Pro Asn Lys Val His Gln Cys His  
1 5 10 15

<210> 45

<211> 15

<212> PRT

<213> Mus musculus

<400> 45

Gln Val Ile Lys Thr Lys Lys Lys Lys Asn Lys His Gln Pro Gly  
1 5 10 15

<210> 46

# COPY

<211> 16  
 <212> PRT  
 <213> Homo sapiens

<400> 46  
 Ser Trp Arg Met Arg Leu Lys Leu Thr Gly Leu Lys Trp Leu Arg Cys  
 1 5 10 15

<210> 47  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 47  
 Asn Pro Cys Ser Asp Glu Glu Trp Cys  
 1 5

<210> 48  
 <211> 6  
 <212> PRT  
 <213> Homo sapiens

<400> 48  
 Tyr Ile Lys Ile Met Ile  
 1 5

<210> 49  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 49  
 Glu Cys Leu Lys Val Met His Val  
 1 5

<210> 50  
 <211> 13  
 <212> PRT  
 <213> Homo sapiens

<400> 50  
 Tyr Lys Cys Ile Leu Val Gln Met Met Tyr Lys Val Leu  
 1 5 10

<210> 51  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 51  
 Val Ser Ala Phe Glu Asn Cys Leu  
 1 5

# COPY


<210> 52  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 52  
Phe Leu Ala Phe Lys Leu Leu Asn Thr Pro  
1 5 10

<210> 53  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 53  
Phe Cys Ile Ala Lys Cys Phe Arg Met Asn Phe Val Ile Val Leu Thr  
1 5 10 15  
Pro Ile Lys Phe Ile Ser Leu  
20





PATENT  
ATTORNEY DOCKET NO. 00742/062004

Certificate of Mailing: Date of Deposit: April 4, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Collette R. D'Amico  
Printed name of person mailing correspondence

Collette R. D'Amico  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thomas L. Benjamin Confirmation No. 7702  
Serial No.: 10/828,815 Art Unit: 1633  
Filed: April 21, 2004 Examiner: Q. J. Li  
Customer No.: 21559  
Title: DIAGNOSING AND TREATING CANCER CELLS USING  
MUTANT VIRUSES

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

This statement is being filed after a first Office Action on the merits, but before the mailing of a final Office Action or a Notice of Allowance. A check for \$180.00 in payment of the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is

04/10/2007 HGUETM01 00000004 10828815

180.00 DP  
02 FC:1806


material to patentability.

If there are any charges or any credits, please apply them to Deposit Account  
No. 03-2095.

Respectfully submitted,

Date:

April 4, 2007

  
\_\_\_\_\_  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045